{
  "domain_code": "PETH",
  "domain_name": "Psychopharmacology & Ethics",
  "total_passages": 750,
  "passages": [
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "5.05: Testimonials",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip The prohibition on soliciting testimonials applies to current therapy clients and others vulnerable to undue influence. The standard does not explicitly prohibit testimonials from former clients, but careful ethical analysis is warranted because former clients may remain vulnerable to the influence of their former therapist",
      "id": "PETH-0001"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "5.01: Avoidance of False or Deceptive Statements",
      "passage_type": "example",
      "passage": "Example A psychologist advertises a \"95% success rate\" for treating anxiety disorders without any empirical basis for this claim. This violates Standard 5.01 because it is a deceptive statement about the degree of success of services. Vague or unsubstantiated claims of effectiveness are prohibited",
      "id": "PETH-0002"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "Overview of Standard 5: Advertising and Other Public Statements",
      "passage_type": "paragraph",
      "passage": "Standard 5 (Advertising and Other Public Statements) of the APA Ethics Code addresses truthfulness in professional representations. Psychologists have an obligation to ensure that all public statements about their services, qualifications, and research are accurate, not deceptive, and do not mislead the public",
      "id": "PETH-0003"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "Overview of Standard 5: Advertising and Other Public Statements",
      "passage_type": "paragraph",
      "passage": "This standard is tested on the EPPP because violations in advertising can directly harm the public and undermine trust in the profession",
      "id": "PETH-0004"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "5.01: Avoidance of False or Deceptive Statements",
      "passage_type": "paragraph",
      "passage": "Psychologists do not knowingly make public statements that are false, deceptive, or fraudulent concerning their research, practice, or other work activities. This prohibition applies to:",
      "id": "PETH-0005"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "5.01: Avoidance of False or Deceptive Statements",
      "passage_type": "paragraph",
      "passage": "Psychologists do not make false, deceptive, or fraudulent statements concerning the degree of success of their services, and they claim only degrees as credentials that were earned from regionally accredited educational institutions or that are the basis for psychology licensure",
      "id": "PETH-0006"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "5.02: Statements by Others",
      "passage_type": "paragraph",
      "passage": "Psychologists who engage others to create or place public statements that promote their professional practice retain professional responsibility for such statements. If psychologists learn of deceptive statements about their work made by others, they make reasonable efforts to correct such statements",
      "id": "PETH-0007"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "5.03: Descriptions of Workshops and Non-Degree-Granting Educational Programs",
      "passage_type": "paragraph",
      "passage": "Psychologists responsible for workshops, seminars, and other non-degree programs ensure that descriptions are accurate regarding:",
      "id": "PETH-0008"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "5.04: Media Presentations",
      "passage_type": "paragraph",
      "passage": "When psychologists provide public advice or comment via print, internet, mail, television, radio, or other electronic media, they take precautions to ensure that statements are:",
      "id": "PETH-0009"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "5.05: Testimonials",
      "passage_type": "paragraph",
      "passage": "Psychologists do not solicit testimonials from current therapy clients or other persons who, because of their particular circumstances, are vulnerable to undue influence. This reflects the power differential in the therapy relationship and the potential for coercion, even if unintentional",
      "id": "PETH-0010"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "5.06: In-Person Solicitation",
      "passage_type": "paragraph",
      "passage": "Psychologists do not engage, directly or through agents, in uninvited in-person solicitation of business from actual or potential therapy clients or other persons who, because of their particular circumstances, are vulnerable to undue influence. This does not prohibit:",
      "id": "PETH-0011"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "The Tyramine Crisis (Hypertensive Crisis)",
      "passage_type": "definition",
      "passage": "Tyramine Crisis Patients taking MAOIs must follow strict dietary restrictions to avoid tyramine -containing foods. Tyramine is normally broken down by MAO in the gut. When MAO is inhibited, tyramine accumulates and causes the release of large amounts of norepinephrine, leading to a potentially fatal hypertensive crisis (severe headache, rapid heart rate, stiff neck, nausea, stroke, death)",
      "id": "PETH-0012"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Serotonin Syndrome",
      "passage_type": "definition",
      "passage": "Serotonin Syndrome Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonergic activity, typically resulting from combining two or more serotonergic medications (e.g., SSRI + MAOI, SSRI + tramadol, SSRI + St. John's Wort). It requires immediate medical attention",
      "id": "PETH-0013"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Side Effects of TCAs",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip TCAs are lethal in overdose due to cardiac arrhythmias. This is a critical clinical consideration and a frequently tested EPPP fact. For this reason, TCAs are prescribed cautiously (if at all) to patients with suicidal ideation. A one-week supply of TCAs can be lethal in overdose",
      "id": "PETH-0014"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "The FDA Black Box Warning",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip The black box warning is limited to ages 24 and under . For adults aged 25-64, antidepressants showed no increased suicidality, and for adults 65+, antidepressants appeared to reduce suicidal risk. The only SSRI FDA-approved for use in children with depression is fluoxetine (ages 8+)",
      "id": "PETH-0015"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Introduction to Antidepressant Medications",
      "passage_type": "paragraph",
      "passage": "Antidepressants are among the most commonly prescribed psychotropic medications. They are used to treat major depressive disorder, anxiety disorders, OCD, PTSD, chronic pain, and other conditions. Understanding the major classes of antidepressants -- their mechanisms, side effects, and clinical considerations -- is essential for the EPPP",
      "id": "PETH-0016"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Introduction to Antidepressant Medications",
      "passage_type": "paragraph",
      "passage": "Antidepressants generally take 2-6 weeks to reach full therapeutic effect, although side effects may begin immediately. This delay is thought to relate to downstream neuroplastic changes rather than the acute increase in neurotransmitter availability",
      "id": "PETH-0017"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Selective Serotonin Reuptake Inhibitors (SSRIs)",
      "passage_type": "paragraph",
      "passage": "SSRIs are the most commonly prescribed class of antidepressants and are generally considered first-line treatment for depression and many anxiety disorders due to their relatively favorable side effect profile",
      "id": "PETH-0018"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Mechanism of Action",
      "passage_type": "paragraph",
      "passage": "SSRIs selectively block the reuptake of serotonin (5-HT) at the presynaptic neuron, increasing the availability of serotonin in the synaptic cleft. They have minimal effects on norepinephrine and dopamine reuptake",
      "id": "PETH-0019"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)",
      "passage_type": "paragraph",
      "passage": "SNRIs block the reuptake of both serotonin and norepinephrine, providing a dual mechanism that may be beneficial for patients who do not respond to SSRIs alone. They are also used for chronic pain conditions, fibromyalgia, and neuropathic pain",
      "id": "PETH-0020"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Tricyclic Antidepressants (TCAs)",
      "passage_type": "paragraph",
      "passage": "TCAs were the first widely used antidepressants but have largely been replaced by SSRIs and SNRIs as first-line treatments due to their significant side effect profile and lethality in overdose. They remain useful for treatment-resistant depression and certain other conditions",
      "id": "PETH-0021"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Mechanism of Action",
      "passage_type": "paragraph",
      "passage": "TCAs block the reuptake of both serotonin and norepinephrine but also block histamine (H1), acetylcholine (muscarinic), and alpha-1 adrenergic receptors, which produces many of their side effects",
      "id": "PETH-0022"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Monoamine Oxidase Inhibitors (MAOIs)",
      "passage_type": "paragraph",
      "passage": "MAOIs are the oldest class of antidepressants. They are now typically reserved for treatment-resistant depression and atypical depression because of their potentially dangerous drug and food interactions",
      "id": "PETH-0023"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Mechanism of Action",
      "passage_type": "paragraph",
      "passage": "MAOIs inhibit the enzyme monoamine oxidase , which normally breaks down serotonin, norepinephrine, and dopamine. By inhibiting this enzyme, MAOIs increase the availability of all three monoamines",
      "id": "PETH-0024"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Drug Interactions with MAOIs",
      "passage_type": "paragraph",
      "passage": "MAOIs have dangerous interactions with many medications, including SSRIs, SNRIs, TCAs, meperidine (Demerol), dextromethorphan, and sympathomimetic drugs. A washout period of at least 2 weeks is required when switching between MAOIs and serotonergic medications (5 weeks for fluoxetine due to its long half-life)",
      "id": "PETH-0025"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Clinical Triad of Serotonin Syndrome",
      "passage_type": "paragraph",
      "passage": "Treatment: Discontinue all serotonergic agents; supportive care; cyproheptadine (a serotonin antagonist) may be used in severe cases; benzodiazepines for agitation",
      "id": "PETH-0026"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "The FDA Black Box Warning",
      "passage_type": "paragraph",
      "passage": "In 2004, the FDA issued a black box warning -- the strongest warning the FDA can require -- for all antidepressants regarding the increased risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24) during the initial weeks of treatment",
      "id": "PETH-0027"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "The Dopamine Hypothesis of Schizophrenia",
      "passage_type": "definition",
      "passage": "Four Dopamine Pathways Mesolimbic: Excess dopamine leads to positive symptoms. Mesocortical: Reduced dopamine leads to negative and cognitive symptoms. Nigrostriatal: Dopamine blockade here causes EPS and tardive dyskinesia. Tuberoinfundibular: Dopamine blockade here increases prolactin, causing hyperprolactinemia",
      "id": "PETH-0028"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Neuroleptic Malignant Syndrome (NMS)",
      "passage_type": "definition",
      "passage": "Neuroleptic Malignant Syndrome (NMS) NMS is a rare but life-threatening medical emergency caused by antipsychotic medications (especially high-potency typicals, but can occur with any antipsychotic). Mortality rate is approximately 10-20% if untreated",
      "id": "PETH-0029"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Extrapyramidal Symptoms (EPS)",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Know the timeline: acute dystonia appears within hours to days , akathisia within days to weeks , parkinsonism within weeks to months , and tardive dyskinesia after months to years of use. TD is the most feared because it may be irreversible and paradoxically may worsen when the offending drug is discontinued",
      "id": "PETH-0030"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Common Atypical Antipsychotics",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Key facts to know: Clozapine = treatment-resistant schizophrenia + agranulocytosis risk + mandatory blood monitoring. Olanzapine = worst metabolic side effects. Aripiprazole = unique partial D2 agonist mechanism. Risperidone = highest prolactin elevation among atypicals",
      "id": "PETH-0031"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Treatment of NMS",
      "passage_type": "example",
      "passage": "NMS vs. Serotonin Syndrome Both involve hyperthermia and altered mental status, but NMS features lead-pipe rigidity and develops over days , while serotonin syndrome features hyperreflexia, clonus, and myoclonus and develops within hours . NMS is caused by dopamine blockade; serotonin syndrome by serotonin excess",
      "id": "PETH-0032"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Introduction to Antipsychotic Medications",
      "passage_type": "paragraph",
      "passage": "Antipsychotic medications (also called neuroleptics) are the primary pharmacological treatment for schizophrenia and other psychotic disorders. They are also used for bipolar disorder, severe agitation, Tourette's disorder, and as adjuncts for treatment-resistant depression. Antipsychotics are divided into two main classes: first-generation (typical) and second-generation (atypical)",
      "id": "PETH-0033"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Introduction to Antipsychotic Medications",
      "passage_type": "paragraph",
      "passage": "For the EPPP, understanding the differences between these two classes -- particularly their mechanisms of action, side effect profiles, and the major adverse effects (EPS, tardive dyskinesia, NMS, and metabolic syndrome) -- is essential",
      "id": "PETH-0034"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "The Dopamine Hypothesis of Schizophrenia",
      "passage_type": "paragraph",
      "passage": "This helps explain why typical antipsychotics, which broadly block dopamine D2 receptors, effectively treat positive symptoms but often worsen negative symptoms and cause movement disorders (due to dopamine blockade in the nigrostriatal pathway)",
      "id": "PETH-0035"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "First-Generation (Typical) Antipsychotics",
      "passage_type": "paragraph",
      "passage": "First-generation antipsychotics (FGAs) work primarily by blocking dopamine D2 receptors . They are classified by potency, which determines their side effect profile",
      "id": "PETH-0036"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Extrapyramidal Symptoms (EPS)",
      "passage_type": "paragraph",
      "passage": "Extrapyramidal symptoms (EPS) are movement disorders caused by dopamine D2 blockade in the nigrostriatal pathway. They are most common with high-potency typical antipsychotics",
      "id": "PETH-0037"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Second-Generation (Atypical) Antipsychotics",
      "passage_type": "paragraph",
      "passage": "Atypical antipsychotics block both dopamine D2 receptors and serotonin 5-HT2A receptors. This dual mechanism, known as serotonin-dopamine antagonism (SDA) , is thought to reduce EPS risk and improve negative symptoms compared to typical antipsychotics",
      "id": "PETH-0038"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Metabolic Syndrome",
      "passage_type": "paragraph",
      "passage": "Second-generation antipsychotics (especially clozapine and olanzapine) carry significant risk of metabolic syndrome , which includes:",
      "id": "PETH-0039"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Metabolic Syndrome",
      "passage_type": "paragraph",
      "passage": "Metabolic monitoring (fasting glucose, lipid panel, weight, waist circumference, blood pressure) is recommended at baseline and at regular intervals for all patients on atypical antipsychotics",
      "id": "PETH-0040"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Clinical Considerations",
      "passage_type": "definition",
      "passage": "Flumazenil (Romazicon) Flumazenil is the specific benzodiazepine antagonist used to reverse benzodiazepine overdose. It competitively blocks the benzodiazepine binding site on the GABA-A receptor. Caution: it can precipitate seizures in patients with benzodiazepine dependence",
      "id": "PETH-0041"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Buspirone (BuSpar)",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Buspirone is a favorite EPPP topic because it differs from benzodiazepines in every key way: slow onset, no sedation, no dependence, no withdrawal, no cross-tolerance with alcohol. If a question asks about an anxiolytic that is safe for patients with a history of substance abuse, buspirone is the answer",
      "id": "PETH-0042"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Memantine (Namenda)",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) work by increasing acetylcholine and are used for mild to moderate Alzheimer's. Memantine is an NMDA antagonist used for moderate to severe Alzheimer's. These drugs slow symptom progression but do NOT cure or reverse the disease",
      "id": "PETH-0043"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Overview",
      "passage_type": "paragraph",
      "passage": "This chapter covers anxiolytics (medications used to treat anxiety disorders), including benzodiazepines and buspirone, as well as anti-dementia medications . These medication classes appear regularly on the EPPP because understanding their mechanisms, side effects, and clinical considerations is essential for psychologists collaborating with prescribers",
      "id": "PETH-0044"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Benzodiazepines",
      "passage_type": "paragraph",
      "passage": "Benzodiazepines are the most commonly prescribed anxiolytics. They enhance the effect of the inhibitory neurotransmitter GABA (gamma-aminobutyric acid) by binding to the GABA-A receptor complex and increasing the frequency of chloride channel opening, leading to neuronal inhibition",
      "id": "PETH-0045"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Anti-Dementia Medications",
      "passage_type": "paragraph",
      "passage": "Currently available medications for Alzheimer's disease provide symptomatic relief but do not halt or reverse the underlying neurodegenerative process",
      "id": "PETH-0046"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Cholinesterase Inhibitors",
      "passage_type": "paragraph",
      "passage": "These drugs inhibit the enzyme acetylcholinesterase , which breaks down acetylcholine, thereby increasing acetylcholine availability in the brain. They are used for mild to moderate Alzheimer's disease",
      "id": "PETH-0047"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Cholinesterase Inhibitors",
      "passage_type": "paragraph",
      "passage": "Common side effects: Nausea, diarrhea, vomiting, decreased appetite, dizziness, bradycardia (all related to increased cholinergic activity)",
      "id": "PETH-0048"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Overview of Standard 9: Assessment",
      "passage_type": "definition",
      "passage": "Assessment vs. Testing Psychological assessment is a comprehensive process that integrates information from multiple sources (tests, interviews, observations, records) to answer referral questions. Psychological testing refers specifically to the administration and scoring of standardized instruments. Assessment is the broader, clinical process; testing is one component of assessment",
      "id": "PETH-0049"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.04(b) -- Absent Client Release",
      "passage_type": "definition",
      "passage": "Test Data vs. Test Materials Test data (9.04) = the client's responses, scores, and behavioral observations -- generally released to the client upon request. Test materials (9.11) = the test itself (questions, stimuli, manuals, scoring keys) -- protected from release to maintain test security. This distinction is frequently tested on the EPPP",
      "id": "PETH-0050"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.01(a) -- Sufficient Information",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip A frequent EPPP scenario: A psychologist is asked to provide a diagnosis or custody recommendation based solely on record review (without examining the individual). Standard 9.01 does not prohibit this, but requires the psychologist to clearly state the limitations and restrict conclusions accordingly. When a personal examination is not practical, the psychologist must document this and qualify their opinions",
      "id": "PETH-0051"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.03(c) -- Court-Ordered or Mandated Assessment",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Court-ordered assessments still require notification -- the psychologist must tell the individual about the nature of services and limits of confidentiality, even though the person cannot refuse the assessment. Informed consent is modified but not eliminated in mandated evaluations",
      "id": "PETH-0052"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.07: Assessment by Unqualified Persons",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip A psychometrist or testing technician may administer and score tests under supervision, but the psychologist retains full responsibility for interpretation and for ensuring the delegate is properly trained. This connects to Standard 2.05 (Delegation of Work to Others)",
      "id": "PETH-0053"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.10: Explaining Assessment Results",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip The default rule is that assessment results should be explained to the individual. Exceptions exist for organizational, forensic, and security contexts -- but only when the person was informed in advance that results would not be shared with them. The EPPP tests whether you understand both the rule and its exceptions",
      "id": "PETH-0054"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.02(b) -- Outdated Norms and Cultural Factors",
      "passage_type": "example",
      "passage": "Example A psychologist administers an intelligence test normed on English-speaking Americans to a recent immigrant whose first language is Spanish. The psychologist must note the cultural and linguistic limitations of the assessment, consider using instruments validated for Spanish speakers, and avoid drawing definitive conclusions about intellectual ability based on the potentially biased results",
      "id": "PETH-0055"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.06: Interpreting Assessment Results",
      "passage_type": "example",
      "passage": "Example A psychologist administering a neuropsychological battery to a client who recently suffered a concussion notes that the client was experiencing headaches and fatigue during testing. The psychologist must note these factors in the report as they may have attenuated test performance, potentially leading to an overestimation of cognitive impairment",
      "id": "PETH-0056"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.08(b) -- Outdated Instruments",
      "passage_type": "example",
      "passage": "Example A psychologist continuing to use the WISC-III (published 1991) for a cognitive evaluation when the WISC-V (published 2014) is available would potentially violate Standard 9.08, as the older version has outdated norms that may not accurately represent current population characteristics. There may be exceptions (e.g., research comparing results across versions), but for clinical purposes the most current edition should be used",
      "id": "PETH-0057"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Overview of Standard 9: Assessment",
      "passage_type": "paragraph",
      "passage": "Standard 9 of the APA Ethics Code governs the ethical conduct of psychological assessment. This is one of the most heavily tested standards on the EPPP because assessment is a core professional activity that directly affects clients' lives -- from clinical diagnoses to forensic evaluations, educational placements, and employment decisions",
      "id": "PETH-0058"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Overview of Standard 9: Assessment",
      "passage_type": "paragraph",
      "passage": "The standard establishes requirements for the proper use, administration, interpretation, and security of psychological tests and assessment instruments. Psychologists must ensure that their assessments are scientifically grounded, culturally appropriate, and conducted with appropriate informed consent",
      "id": "PETH-0059"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.01: Bases for Assessments",
      "passage_type": "paragraph",
      "passage": "Psychologists base the opinions contained in their recommendations, reports, and diagnostic or evaluative statements, including forensic testimony, on information and techniques sufficient to substantiate their findings",
      "id": "PETH-0060"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.01(a) -- Sufficient Information",
      "passage_type": "paragraph",
      "passage": "Psychologists provide opinions only after they have conducted an examination of the individual adequate to support their statements or conclusions. When a personal examination is not practical, psychologists document the efforts they made and the results of those efforts, clarify the probable impact of their limited information on the reliability and validity of their opinions, and appropriately limit the nature and extent of their conclusions or recommendations",
      "id": "PETH-0061"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.01(b) -- Limitations When Personal Examination Is Not Possible",
      "passage_type": "paragraph",
      "passage": "Except as noted in 9.01(c), psychologists provide opinions of the psychological characteristics of individuals only after they have conducted an examination adequate to support their statements. When, despite reasonable efforts, such an examination is not practical, psychologists document their efforts and the impact on conclusions",
      "id": "PETH-0062"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.01(c) -- Record Review Without Examination",
      "passage_type": "paragraph",
      "passage": "When psychologists conduct a record review or provide consultation or supervision and an individual examination is not warranted or necessary, they explain this and the sources of information on which they based their conclusions and recommendations",
      "id": "PETH-0063"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.02: Use of Assessments",
      "passage_type": "paragraph",
      "passage": "Psychologists administer, adapt, score, interpret, or use assessment techniques, interviews, tests, or instruments in a manner and for purposes that are appropriate in light of the research on or evidence of the usefulness and proper application of the techniques",
      "id": "PETH-0064"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.02(a) -- Appropriate Use",
      "passage_type": "paragraph",
      "passage": "Psychologists use assessment instruments whose validity and reliability have been established for use with members of the population tested. When such validity or reliability has not been established, psychologists describe the strengths and limitations of test results and interpretation",
      "id": "PETH-0065"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.02(b) -- Outdated Norms and Cultural Factors",
      "passage_type": "paragraph",
      "passage": "Psychologists use assessment instruments whose validity and reliability have been established for the specific purpose and population. When assessing individuals from populations not represented in the normative sample, psychologists must consider cultural, linguistic, and individual factors that may affect interpretation and clearly note these limitations in reports",
      "id": "PETH-0066"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.03(a) -- Explaining the Purpose",
      "passage_type": "paragraph",
      "passage": "Informed consent includes an explanation of the nature and purpose of the assessment, fees, involvement of third parties, and limits of confidentiality in a language reasonably understandable to the person being assessed or their legal representative",
      "id": "PETH-0067"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.03(b) -- Individuals Lacking Capacity",
      "passage_type": "paragraph",
      "passage": "For persons who lack the capacity to consent (e.g., due to cognitive impairment), psychologists provide appropriate explanation, seek the person's assent, consider preferences and best interests, and obtain consent from a legally authorized person",
      "id": "PETH-0068"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.03(c) -- Court-Ordered or Mandated Assessment",
      "passage_type": "paragraph",
      "passage": "When services are court ordered or otherwise mandated, psychologists inform the individual of the nature of the anticipated services, including whether the services are court ordered or mandated and any limits of confidentiality, before proceeding",
      "id": "PETH-0069"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.04: Release of Test Data",
      "passage_type": "paragraph",
      "passage": "Test data refers to raw and scaled scores, client responses to test questions or stimuli, and psychologists' notes and recordings concerning client statements and behavior during an examination. Test data are distinguished from test materials (manuals, instruments, protocols, test questions or stimuli)",
      "id": "PETH-0070"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.04(a) -- Client Request",
      "passage_type": "paragraph",
      "passage": "Pursuant to a client release, psychologists provide test data to the client or other persons identified in the release. Psychologists may refrain from releasing test data to protect a client or others from substantial harm or misuse or misrepresentation of the data or the test, recognizing that in many instances release of confidential information under these circumstances is regulated by law",
      "id": "PETH-0071"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.05: Test Construction",
      "passage_type": "paragraph",
      "passage": "Psychologists who develop tests and other assessment techniques use appropriate psychometric procedures and current scientific or professional knowledge for test design, standardization, validation, reduction or elimination of bias, and recommendations for use",
      "id": "PETH-0072"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.05: Test Construction",
      "passage_type": "paragraph",
      "passage": "This standard applies to psychologists who create new assessment instruments and requires that such instruments meet accepted standards for reliability, validity, and fairness",
      "id": "PETH-0073"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.06: Interpreting Assessment Results",
      "passage_type": "paragraph",
      "passage": "When interpreting assessment results, including automated interpretations, psychologists take into account the purpose of the assessment as well as the various test factors, test-taking abilities, and other characteristics of the person being assessed, such as situational, personal, linguistic, and cultural differences, that might affect psychologists' judgments or reduce the accuracy of their interpretations. They indicate any significant limitations of their interpretations",
      "id": "PETH-0074"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.07: Assessment by Unqualified Persons",
      "passage_type": "paragraph",
      "passage": "Psychologists do not promote the use of psychological assessment techniques by unqualified persons, except when such use is conducted for training purposes with appropriate supervision. When psychologists delegate scoring and interpretation to others (e.g., technicians, computer scoring services), they retain responsibility for the appropriate application, interpretation, and use of assessment instruments",
      "id": "PETH-0075"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.08(a) -- Obsolete Tests",
      "passage_type": "paragraph",
      "passage": "Psychologists do not base their assessment or intervention decisions or recommendations on data or test results that are outdated for the current purpose",
      "id": "PETH-0076"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.08(b) -- Outdated Instruments",
      "passage_type": "paragraph",
      "passage": "Psychologists do not base decisions or recommendations on tests and measures that are obsolete and not useful for the current purpose",
      "id": "PETH-0077"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.09: Test Scoring and Interpretation Services",
      "passage_type": "paragraph",
      "passage": "Psychologists who offer assessment or scoring services to other professionals accurately describe the purpose, norms, validity, reliability, and applications of the procedures and any special qualifications applicable to their use. Psychologists select scoring and interpretation services (including automated services) on the basis of evidence of the validity of the program and procedures as well as on other appropriate considerations",
      "id": "PETH-0078"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Computer-Based Test Interpretation (CBTI)",
      "passage_type": "paragraph",
      "passage": "Psychologists who use computer-based test interpretation services must understand the limitations of such services. Automated interpretations are probabilistic statements based on group data and may not apply to a specific individual. The psychologist, not the computer program, is responsible for the final clinical interpretation",
      "id": "PETH-0079"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.10: Explaining Assessment Results",
      "passage_type": "paragraph",
      "passage": "Regardless of whether the scoring and interpretation are done by psychologists, by employees or assistants, or by automated or other outside services, psychologists take reasonable steps to ensure that explanations of results are given to the individual or designated representative unless the nature of the relationship precludes provision of an explanation of results (such as in some organizational consulting, preemployment or security screenings, and forensic evaluations), and this fact has been clearly explained to the person being assessed in advance",
      "id": "PETH-0080"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.11: Maintaining Test Security",
      "passage_type": "paragraph",
      "passage": "The term test materials refers to manuals, instruments, protocols, and test questions or stimuli. Psychologists make reasonable efforts to maintain the integrity and security of test materials and other assessment techniques consistent with law and contractual obligations, and in a manner that permits adherence to this Ethics Code",
      "id": "PETH-0081"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Balancing Security and Client Rights",
      "passage_type": "paragraph",
      "passage": "Test security concerns must be balanced against clients' rights to access their own data (9.04). The distinction between test data (which can be released to clients) and test materials (which should be protected) is critical. For example:",
      "id": "PETH-0082"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Overview of Standard 2: Competence",
      "passage_type": "definition",
      "passage": "Competence Defined Professional competence refers to the ability to effectively and appropriately apply the knowledge, skills, and attitudes necessary to fulfill one's professional roles. It encompasses both intellectual understanding and practical skill, shaped by ongoing education and experience",
      "id": "PETH-0083"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Standard 2.04: Bases for Scientific and Professional Judgments",
      "passage_type": "definition",
      "passage": "Evidence-Based Practice The APA Presidential Task Force (2006) defined evidence-based practice in psychology (EBPP) as the integration of the best available research with clinical expertise in the context of patient characteristics, culture, and preferences. EBPP is the operational expression of Standard 2.04",
      "id": "PETH-0084"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Standard 2.02: Providing Services in Emergencies",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Standard 2.02 is the emergency exception to competence boundaries. On the EPPP, if a question describes a crisis situation (e.g., a natural disaster) where no other provider is available, the psychologist may provide services outside their typical area of competence. However, this is temporary -- they must stop once the emergency ends or a qualified provider is found",
      "id": "PETH-0085"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "2.06(b) -- Taking Appropriate Action",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip EPPP questions about impaired psychologists test whether you know that the ethical response involves the psychologist taking responsibility for their own impairment. The first step is self-awareness; the second is taking appropriate corrective action (consultation, therapy, limiting practice). Colleagues who become aware of an impaired psychologist should attempt informal resolution (Standard 1.04) by speaking to the psychologist directly",
      "id": "PETH-0086"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "2.01(b) -- New Areas of Practice",
      "passage_type": "example",
      "passage": "Example A psychologist trained in cognitive-behavioral therapy wants to begin providing telepsychology services. Under 2.01(b), the psychologist should obtain training in telehealth best practices, learn the relevant technology, understand the legal requirements of interstate practice, and seek consultation from colleagues experienced in telepsychology before beginning",
      "id": "PETH-0087"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Standard 2.05: Delegation of Work to Others",
      "passage_type": "example",
      "passage": "Example A psychologist delegates psychological testing administration to a psychometrist. Under 2.05, the psychologist must ensure the psychometrist is properly trained in administering the specific test, must supervise the work appropriately, and retains ultimate responsibility for the interpretation and clinical use of test results",
      "id": "PETH-0088"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Competence vs. Scope of Practice",
      "passage_type": "example",
      "passage": "Example A state's scope of practice for psychologists may include neuropsychological assessment. However, a psychologist trained only in clinical therapy has not established individual competence in neuropsychological assessment, even though it falls within the profession's legal scope of practice. The psychologist should not perform neuropsychological assessments without obtaining appropriate training",
      "id": "PETH-0089"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Overview of Standard 2: Competence",
      "passage_type": "paragraph",
      "passage": "Standard 2 of the APA Ethics Code addresses the foundational requirement that psychologists practice only within the boundaries of their competence , based on their education, training, supervised experience, consultation, study, or professional experience. Competence is not a fixed trait but a dynamic, evolving professional obligation",
      "id": "PETH-0090"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Overview of Standard 2: Competence",
      "passage_type": "paragraph",
      "passage": "This standard is one of the most frequently tested areas on the EPPP because it intersects with virtually every professional activity a psychologist undertakes -- from therapy and assessment to research, teaching, and consultation",
      "id": "PETH-0091"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Standard 2.01: Boundaries of Competence",
      "passage_type": "paragraph",
      "passage": "This subsection establishes the fundamental rule: psychologists provide services, teach, and conduct research only within the boundaries of their competence",
      "id": "PETH-0092"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "2.01(a) -- Education, Training, and Experience",
      "passage_type": "paragraph",
      "passage": "Psychologists provide services in areas in which they have established competence through education, training, supervised experience, consultation, study, or professional experience. Competence is typically demonstrated through:",
      "id": "PETH-0093"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "2.01(b) -- New Areas of Practice",
      "passage_type": "paragraph",
      "passage": "When psychologists wish to provide services in areas where recognized professional standards do not yet exist, they take reasonable steps to ensure the competence of their work and to protect clients, students, and others from harm. This provision acknowledges that psychology is an evolving field",
      "id": "PETH-0094"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "2.01(c) -- Unfamiliar Populations",
      "passage_type": "paragraph",
      "passage": "In areas where recognized training standards for serving specific populations do not yet exist, psychologists with closely related prior training or experience may provide such services, with appropriate study, training, supervision, and/or consultation. This is particularly relevant to working with diverse cultural, ethnic, or linguistic groups",
      "id": "PETH-0095"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "2.01(d) -- Forensic Activities",
      "passage_type": "paragraph",
      "passage": "When psychologists are asked to provide services to individuals for whom appropriate mental health services are not available and for which psychologists have not obtained the requisite competence, they may provide services with the closest related competence -- but only until a qualified provider becomes available",
      "id": "PETH-0096"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "2.01(e) -- New Techniques",
      "passage_type": "paragraph",
      "passage": "In emerging areas where generally recognized standards for preparatory training do not yet exist, psychologists take reasonable steps to ensure competence and protect clients from harm",
      "id": "PETH-0097"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "2.01(f) -- Familiarity with Relevant Factors",
      "passage_type": "paragraph",
      "passage": "When assuming forensic roles, psychologists must be knowledgeable about the judicial or administrative rules governing their participation",
      "id": "PETH-0098"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Standard 2.02: Providing Services in Emergencies",
      "passage_type": "paragraph",
      "passage": "In emergencies, when psychologists are asked to provide services to individuals for whom other mental health services are not available, psychologists may provide such services to ensure that services are not denied. The services are discontinued as soon as the emergency has ended or appropriate services are available",
      "id": "PETH-0099"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Continuing Education Requirements",
      "passage_type": "paragraph",
      "passage": "Most state licensing boards require psychologists to complete a specified number of continuing education (CE) credits during each renewal period (typically 20-40 hours per biennium). Many states require specific CE topics such as ethics, cultural diversity, or evidence-based practice",
      "id": "PETH-0100"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "The Competence Constellation Model",
      "passage_type": "paragraph",
      "passage": "Rodolfa et al. (2005) proposed a competence constellation model that distinguishes between foundational competencies and functional competencies:",
      "id": "PETH-0101"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Standard 2.04: Bases for Scientific and Professional Judgments",
      "passage_type": "paragraph",
      "passage": "Psychologists' work must be based on established scientific and professional knowledge of the discipline. This means psychologists should rely on:",
      "id": "PETH-0102"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Standard 2.06: Personal Problems and Conflicts",
      "passage_type": "paragraph",
      "passage": "This subsection addresses situations where a psychologist's personal problems may interfere with professional functioning",
      "id": "PETH-0103"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "2.06(a) -- Awareness of Personal Problems",
      "passage_type": "paragraph",
      "passage": "Psychologists refrain from initiating an activity when they know or should know that there is a substantial likelihood that their personal problems will prevent them from performing their work-related activities in a competent manner",
      "id": "PETH-0104"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "2.06(b) -- Taking Appropriate Action",
      "passage_type": "paragraph",
      "passage": "When psychologists become aware of personal problems that may interfere with their performing work-related duties adequately, they take appropriate measures such as:",
      "id": "PETH-0105"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Scope of Practice",
      "passage_type": "paragraph",
      "passage": "Scope of practice refers to the legally defined range of activities that a licensed professional is authorized to perform. Scope of practice is established by state licensing laws and varies across jurisdictions",
      "id": "PETH-0106"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "7.05: Mandatory Individual or Group Therapy",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Standard 7.05 is often tested: If a program mandates personal therapy, students must be able to choose their own therapist from outside the program. A faculty member who evaluates the student should NEVER be that student's therapist, as this creates an impermissible dual relationship",
      "id": "PETH-0107"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "Overview of Standard 7: Education and Training",
      "passage_type": "paragraph",
      "passage": "Standard 7 (Education and Training) of the APA Ethics Code governs the ethical conduct of psychologists in academic and training settings. This standard addresses program design, accuracy in teaching, student disclosure requirements, mandatory therapy, performance evaluation, and prohibitions on sexual relationships with students and supervisees",
      "id": "PETH-0108"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "Overview of Standard 7: Education and Training",
      "passage_type": "paragraph",
      "passage": "These provisions protect students and supervisees who are in inherently unequal power relationships with their educators and training supervisors",
      "id": "PETH-0109"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "7.01: Design of Education and Training Programs",
      "passage_type": "paragraph",
      "passage": "Psychologists responsible for education and training programs take reasonable steps to ensure that programs are designed to provide appropriate knowledge and proper experiences, and that the programs meet the requirements for licensure, certification, or other professional goals described in the program",
      "id": "PETH-0110"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "7.02: Descriptions of Education and Training Programs",
      "passage_type": "paragraph",
      "passage": "Psychologists responsible for education and training programs take reasonable steps to ensure accurate descriptions of program content, training goals and objectives, stipends and benefits, and requirements for completion including required supervised experience and practicum",
      "id": "PETH-0111"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "7.03: Accuracy in Teaching",
      "passage_type": "paragraph",
      "passage": "Psychologists take reasonable steps to ensure that course syllabi are accurate regarding subject matter, basis for evaluating progress, and the nature of course experiences. When teaching, psychologists present information accurately and do not deliberately teach false or misleading information",
      "id": "PETH-0112"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "7.04: Student Disclosure of Personal Information",
      "passage_type": "paragraph",
      "passage": "Psychologists do not require students to disclose personal information in course- or program-related activities regarding:",
      "id": "PETH-0113"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "7.04: Student Disclosure of Personal Information",
      "passage_type": "paragraph",
      "passage": "Exception: Such disclosure may be required if (a) the program clearly identified this requirement in its admissions materials, or (b) the information is necessary to evaluate or obtain assistance for students whose personal problems could reasonably be judged to be preventing them from performing competently or posing a threat to others",
      "id": "PETH-0114"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "7.05: Mandatory Individual or Group Therapy",
      "passage_type": "paragraph",
      "passage": "When a program requires individual or group therapy as part of its training, students are permitted to select the therapist from practitioners unaffiliated with the program. Faculty who are or are likely to be responsible for evaluating students' academic performance do not themselves provide that therapy",
      "id": "PETH-0115"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "7.06: Assessing Student and Supervisee Performance",
      "passage_type": "paragraph",
      "passage": "Psychologists in academic and supervisory roles establish a timely and specific process for providing feedback to students and supervisees. Evaluations must be based on actual performance and relevant, established program requirements",
      "id": "PETH-0116"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "7.07: Sexual Relationships with Students and Supervisees",
      "passage_type": "paragraph",
      "passage": "Psychologists do not engage in sexual relationships with students or supervisees who are in their department, agency, or training center, or over whom psychologists have or are likely to have evaluative authority. This prohibition is absolute and has no exceptions",
      "id": "PETH-0117"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Introduction to the APA Ethics Code",
      "passage_type": "definition",
      "passage": "Key Distinction Aspirational principles (General Principles A-E) describe the highest ideals of the profession but are not enforceable. Enforceable standards (Standards 1-10) set minimum behavioral expectations and can be used as the basis for ethics complaints and disciplinary action",
      "id": "PETH-0118"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Canadian Code Model (Sinclair et al.)",
      "passage_type": "definition",
      "passage": "Key Difference Unlike the APA Ethics Code (which does not rank its General Principles), the Canadian Code explicitly prioritizes principles so that when two principles conflict, the higher-ranked principle takes precedence",
      "id": "PETH-0119"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "General Principles (Aspirational)",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip A common EPPP question format presents a scenario and asks which General Principle applies. Remember: Principle B (Fidelity and Responsibility) is the one that mentions pro bono work and concern for colleagues' ethical behavior. Principle D (Justice) specifically addresses fairness and bias",
      "id": "PETH-0120"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Applicability and Enforcement",
      "passage_type": "example",
      "passage": "Example A state law requires psychologists to report suspected child abuse. Even if a psychologist feels that reporting might damage the therapeutic relationship, the legal mandate overrides the ethical preference for maintaining confidentiality. Conversely, if the Ethics Code requires informed consent in a situation where local law is silent, the psychologist should still obtain informed consent",
      "id": "PETH-0121"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Introduction to the APA Ethics Code",
      "passage_type": "paragraph",
      "passage": "The Ethical Principles of Psychologists and Code of Conduct (commonly called the APA Ethics Code) was most recently revised in 2017 and serves as the primary ethical guide for psychologists in the United States. It governs the professional, scientific, and educational activities of psychologists and applies to all APA members regardless of their role",
      "id": "PETH-0122"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Introduction to the APA Ethics Code",
      "passage_type": "paragraph",
      "passage": "The Ethics Code is structured to include both broad aspirational goals and specific enforceable rules. Understanding this dual nature is critical for the EPPP, as exam questions frequently test whether a given statement is aspirational or enforceable",
      "id": "PETH-0123"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "The Preamble",
      "passage_type": "paragraph",
      "passage": "The Preamble describes the mission of psychology and the purpose of the Ethics Code. It acknowledges that psychologists occupy roles as researchers, educators, diagnosticians, therapists, supervisors, consultants, administrators, social interventionists, and expert witnesses. The Preamble stresses that the Code applies to these roles only in the context of scientific, educational, or professional activities",
      "id": "PETH-0124"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "General Principles (Aspirational)",
      "passage_type": "paragraph",
      "passage": "The five General Principles guide psychologists toward ethical ideals. For the EPPP, memorize each principle and know that they are aspirational, not enforceable",
      "id": "PETH-0125"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Ethical Standards Overview (Standards 1-10)",
      "passage_type": "paragraph",
      "passage": "The ten Ethical Standards are the enforceable component of the Ethics Code. Each standard contains multiple subsections addressing specific behaviors and obligations",
      "id": "PETH-0126"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Detailed Coverage of Each Standard",
      "passage_type": "paragraph",
      "passage": "Each of the ten Ethical Standards is covered in detail in its own chapter. Standard 1 (Resolving Ethical Issues) is covered in the next chapter. Standards 2 through 8 each have dedicated chapters in Part A of this domain, while Standards 9 (Assessment) and 10 (Therapy) are also covered separately",
      "id": "PETH-0127"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Ethics Decision-Making Models",
      "passage_type": "paragraph",
      "passage": "The Ethics Code alone does not resolve every ethical dilemma. Several decision-making models provide structured approaches for navigating complex situations",
      "id": "PETH-0128"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Canadian Code Model (Sinclair et al.)",
      "passage_type": "paragraph",
      "passage": "The Canadian Psychological Association's four-principle model ranks ethical principles hierarchically when they conflict:",
      "id": "PETH-0129"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "The Role of Consultation",
      "passage_type": "paragraph",
      "passage": "Across all decision-making models, consultation with knowledgeable colleagues is strongly emphasized. When facing an ethical dilemma, psychologists should document the steps taken, the reasoning behind their decision, and any consultations obtained. This documentation serves as evidence of the psychologist's good-faith effort to act ethically",
      "id": "PETH-0130"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Virtue Ethics Approach",
      "passage_type": "paragraph",
      "passage": "Some ethicists (e.g., Meara, Schmidt, & Day, 1996) argue that ethical codes focused solely on rules are insufficient. A virtue ethics approach asks not just \"what should I do?\" but \"what kind of person should I be?\" The virtues of prudence, integrity, respectfulness, and benevolence complement the enforceable standards of the Ethics Code",
      "id": "PETH-0131"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "When Multiple Relationships Are Permissible",
      "passage_type": "definition",
      "passage": "Key Distinction: Boundary Crossings vs. Boundary Violations A boundary crossing is a deviation from standard clinical practice that is not harmful and may even be therapeutic (e.g., attending a client's graduation, brief self-disclosure, accepting a small culturally appropriate gift). A boundary violation is a deviation that exploits or harms the client (e.g., entering a sexual relationship, engaging in a business partnership). Not all boundary crossings become violations",
      "id": "PETH-0132"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.01: Unfair Discrimination",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Note the word \"unfair\" in this standard. Not all differential treatment constitutes discrimination. For example, using age-appropriate assessment instruments or adapting therapy techniques for clients with disabilities is appropriate differential treatment, not unfair discrimination",
      "id": "PETH-0133"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Sexual Relationships: Standards 3.05 and 10.05-10.08",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip The two-year rule (10.08) is one of the most tested facts in the Ethics domain. Remember: the two-year clock starts at termination , not at the start of therapy. Even after two years, the burden falls on the psychologist to prove the relationship is not exploitative. Most ethics scholars advise that sexual relationships with former clients should always be avoided",
      "id": "PETH-0134"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Managing Unavoidable Multiple Relationships",
      "passage_type": "example",
      "passage": "Example A psychologist in a rural community discovers that a new therapy client is the parent of a child on the psychologist's daughter's sports team. This creates a social-professional overlap. Because the psychologist is the only provider within 100 miles, referral may not be practical. The ethical response is to carefully manage the boundaries, document the decision-making process, and consult with a colleague about how to minimize potential conflicts",
      "id": "PETH-0135"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.06: Conflict of Interest",
      "passage_type": "example",
      "passage": "Example A psychologist is hired by a company to conduct fitness-for-duty evaluations. The psychologist also owns stock in a competitor company. If the evaluation results could affect the stock value of the competitor, a conflict of interest exists. The psychologist should disclose the conflict or decline the engagement",
      "id": "PETH-0136"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Overview of Standard 3: Human Relations",
      "passage_type": "paragraph",
      "passage": "Standard 3 of the APA Ethics Code addresses the complexities of professional relationships, including multiple relationships , unfair discrimination, sexual harassment, conflicts of interest, and exploitation. These topics are among the most heavily tested on the EPPP because they arise in nearly every professional context",
      "id": "PETH-0137"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Overview of Standard 3: Human Relations",
      "passage_type": "paragraph",
      "passage": "The standard applies across all professional roles -- therapy, assessment, research, teaching, supervision, and consultation -- and emphasizes that the power differential inherent in psychologists' roles creates special obligations to protect those with whom they work",
      "id": "PETH-0138"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.01: Unfair Discrimination",
      "passage_type": "paragraph",
      "passage": "Psychologists do not engage in unfair discrimination based on age, gender, gender identity, race, ethnicity, culture, national origin, religion, sexual orientation, disability, socioeconomic status, or any basis proscribed by law. This applies to all professional activities",
      "id": "PETH-0139"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.02: Sexual Harassment",
      "passage_type": "paragraph",
      "passage": "Psychologists do not engage in sexual harassment , which consists of sexual solicitation, physical advances, or verbal or nonverbal conduct that is sexual in nature and that either:",
      "id": "PETH-0140"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.02: Sexual Harassment",
      "passage_type": "paragraph",
      "passage": "Sexual harassment can occur between any parties in a professional relationship: psychologist-client, supervisor-supervisee, professor-student, or between colleagues",
      "id": "PETH-0141"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.05: Multiple Relationships",
      "passage_type": "paragraph",
      "passage": "A multiple relationship (also called a dual relationship) occurs when a psychologist is in a professional role with a person and simultaneously:",
      "id": "PETH-0142"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "When Multiple Relationships Are Permissible",
      "passage_type": "paragraph",
      "passage": "The Ethics Code acknowledges that multiple relationships that would not reasonably be expected to cause impairment or risk exploitation or harm are not unethical . This is an important nuance for the EPPP",
      "id": "PETH-0143"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Managing Unavoidable Multiple Relationships",
      "passage_type": "paragraph",
      "passage": "If a potentially harmful multiple relationship has arisen due to unforeseen factors, the psychologist takes reasonable steps to resolve it with due regard for the best interests of the affected person and maximal compliance with the Ethics Code. Strategies include:",
      "id": "PETH-0144"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.04: Avoiding Harm",
      "passage_type": "paragraph",
      "passage": "Psychologists take reasonable steps to avoid harming their clients, students, supervisees, research participants, organizational clients, and others with whom they work, and to minimize harm where it is foreseeable and unavoidable",
      "id": "PETH-0145"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.06: Conflict of Interest",
      "passage_type": "paragraph",
      "passage": "Psychologists refrain from taking on a professional role when personal, scientific, professional, legal, financial, or other interests or relationships could reasonably be expected to:",
      "id": "PETH-0146"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.08: Exploitative Relationships",
      "passage_type": "paragraph",
      "passage": "Psychologists do not exploit persons over whom they have supervisory, evaluative, or other authority, such as clients, students, supervisees, research participants, and employees. Exploitation can be financial, sexual, emotional, or otherwise take advantage of the power differential",
      "id": "PETH-0147"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Informed Consent in Therapy (Standard 10.01)",
      "passage_type": "paragraph",
      "passage": "When the client is legally incapable of giving informed consent (e.g., a minor or an individual adjudicated incompetent), the psychologist provides an appropriate explanation, seeks the individual's assent, considers preferences and best interests, and obtains appropriate permission from a legally authorized person",
      "id": "PETH-0148"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Lithium (Eskalith, Lithobid)",
      "passage_type": "definition",
      "passage": "Lithium Monitoring Baseline labs before starting lithium include: renal function (BUN, creatinine), thyroid function (TSH), CBC, EKG, and pregnancy test. Lithium levels are drawn 12 hours after the last dose (trough level). Regular monitoring of renal and thyroid function is required throughout treatment",
      "id": "PETH-0149"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Lamotrigine (Lamictal)",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Key associations: Lithium = thyroid and kidney monitoring + Ebstein's anomaly. Valproate = hepatotoxicity + neural tube defects + contraindicated in pregnancy. Carbamazepine = aplastic anemia + Stevens-Johnson syndrome + enzyme induction. Lamotrigine = Stevens-Johnson syndrome + slow titration required + best for bipolar depression prevention",
      "id": "PETH-0150"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Mood Stabilizers",
      "passage_type": "paragraph",
      "passage": "Mood stabilizers are used primarily for bipolar disorder to treat acute mania, prevent mood episodes, and stabilize mood fluctuations. Lithium is the classic mood stabilizer, but several anticonvulsant medications also serve this function",
      "id": "PETH-0151"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Lithium (Eskalith, Lithobid)",
      "passage_type": "paragraph",
      "passage": "Lithium remains the gold standard treatment for bipolar disorder, particularly for classic (euphoric) mania. It is also the only mood stabilizer with strong evidence for reducing suicidality",
      "id": "PETH-0152"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacokinetics (ADME)",
      "passage_type": "definition",
      "passage": "Pharmacokinetics Pharmacokinetics describes \"what the body does to the drug\" -- the processes of Absorption, Distribution, Metabolism, and Excretion (ADME) that determine a drug's concentration at its site of action over time",
      "id": "PETH-0153"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Half-Life and Steady State",
      "passage_type": "definition",
      "passage": "Half-Life (t1/2) Half-life is the time required for the plasma concentration of a drug to decrease by 50%. It is the single most important pharmacokinetic parameter for understanding dosing frequency, time to steady state, and duration of drug effect after discontinuation",
      "id": "PETH-0154"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "The CYP450 Enzyme System",
      "passage_type": "definition",
      "passage": "Cytochrome P450 (CYP450) The CYP450 system is a superfamily of liver enzymes responsible for the Phase I metabolism of approximately 75% of all clinically used drugs. Understanding CYP450 isoenzymes is essential for predicting drug-drug interactions -- one of the most commonly tested pharmacology topics on the EPPP",
      "id": "PETH-0155"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacodynamics",
      "passage_type": "definition",
      "passage": "Pharmacodynamics Pharmacodynamics describes \"what the drug does to the body\" -- how a drug produces its effects by interacting with molecular targets (typically receptors) in the body",
      "id": "PETH-0156"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Potency vs. Efficacy",
      "passage_type": "definition",
      "passage": "Potency vs. Efficacy Potency refers to the amount of drug needed to produce a given effect (related to ED50) -- a more potent drug requires a lower dose. Efficacy refers to the maximum effect a drug can produce regardless of dose. A drug can be highly potent but have low maximum efficacy (and vice versa). For clinical purposes, efficacy is generally more important than potency -- a drug that requires a higher dose but achieves a better outcome is preferable to one that works at a lower dose but has a lower ceiling of effect",
      "id": "PETH-0157"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Serotonin (5-HT)",
      "passage_type": "definition",
      "passage": "Serotonin (5-Hydroxytryptamine, 5-HT) Serotonin is a monoamine neurotransmitter synthesized from the amino acid tryptophan. It is produced primarily in the raphe nuclei of the brainstem, with projections throughout the cortex, limbic system, hypothalamus, and spinal cord",
      "id": "PETH-0158"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Norepinephrine (NE)",
      "passage_type": "definition",
      "passage": "Norepinephrine (Noradrenaline) Norepinephrine is a catecholamine neurotransmitter synthesized from dopamine. The primary CNS source is the locus coeruleus , a small nucleus in the brainstem pons that sends diffuse projections throughout the brain",
      "id": "PETH-0159"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Dopamine (DA)",
      "passage_type": "definition",
      "passage": "Dopamine Dopamine is a catecholamine neurotransmitter with diverse functions. Unlike serotonin and norepinephrine, which have single primary nuclei, dopamine is organized into distinct pathways with different functions -- and understanding these pathways is essential for understanding both the therapeutic effects and side effects of antipsychotics",
      "id": "PETH-0160"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "GABA (Gamma-Aminobutyric Acid)",
      "passage_type": "definition",
      "passage": "GABA GABA is the brain's primary inhibitory neurotransmitter, found in approximately 30-40% of all synapses. Reduced GABAergic activity is implicated in anxiety disorders, epilepsy, insomnia, and alcohol withdrawal",
      "id": "PETH-0161"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Glutamate",
      "passage_type": "definition",
      "passage": "Glutamate Glutamate is the brain's primary excitatory neurotransmitter, present in the majority of excitatory synapses. It plays a central role in synaptic plasticity, learning, memory, and neurodevelopment. Excessive glutamate activity can lead to excitotoxicity -- neuronal damage and death caused by overstimulation",
      "id": "PETH-0162"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Acetylcholine (ACh)",
      "passage_type": "definition",
      "passage": "Acetylcholine Acetylcholine (ACh) is a neurotransmitter involved in both the central and peripheral nervous systems. In the CNS, the primary cholinergic nuclei include the nucleus basalis of Meynert (projecting to the cortex) and the septal nuclei (projecting to the hippocampus). Degeneration of cholinergic neurons in the nucleus basalis of Meynert is a hallmark of Alzheimer's disease",
      "id": "PETH-0163"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Anticholinergic Effects",
      "passage_type": "definition",
      "passage": "Memory Aid Anticholinergic side effects are remembered as: \"Can't see, can't pee, can't spit, can't sh*t\" (blurred vision, urinary retention, dry mouth, constipation). In elderly patients, the additional cognitive effects (\"can't remember\") are a major concern, as anticholinergic burden is associated with increased risk of falls, delirium, and long-term dementia risk",
      "id": "PETH-0164"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Geriatric Considerations",
      "passage_type": "definition",
      "passage": "\"Start Low, Go Slow\" The \"start low, go slow\" principle is the cardinal rule of geriatric psychopharmacology. It means initiating medications at lower doses than typically used for younger adults (often 50% of the standard starting dose) and titrating upward gradually, allowing extra time to assess both therapeutic response and side effects at each dose level. This approach accounts for reduced metabolism, increased drug sensitivity, and the higher risk of adverse effects in elderly patients",
      "id": "PETH-0165"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Metabolism (Biotransformation)",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Some drugs (called prodrugs ) are inactive when administered and must be metabolized to their active form. Others produce active metabolites that extend the drug's duration of action (e.g., fluoxetine's metabolite norfluoxetine has a half-life of 4-16 days). The distinction between Phase I and Phase II metabolism is commonly tested",
      "id": "PETH-0166"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Major CYP450 Isoenzymes",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip When a CYP450 inhibitor is co-administered with a substrate of that enzyme, the substrate's metabolism is slowed , leading to increased plasma levels and potentially toxicity. When an inducer is added, the substrate is metabolized faster , leading to decreased plasma levels and potentially therapeutic failure. Example: adding fluoxetine (CYP2D6 inhibitor) to a patient on haloperidol (CYP2D6 substrate) will raise haloperidol levels, increasing the risk of EPS and other side effects",
      "id": "PETH-0167"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Wide Therapeutic Index Drugs",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip The EPPP frequently tests the clinical monitoring requirements for narrow therapeutic index drugs , especially lithium. Know the therapeutic range, signs of toxicity, and factors that alter lithium levels (dehydration, NSAIDs, diuretics, sodium restriction). Lithium toxicity presents as coarse tremor, ataxia, slurred speech, confusion, and can progress to seizures, coma, and death",
      "id": "PETH-0168"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacodynamic Interactions",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Key drug-drug interactions to know: (1) SSRI + MAOI = serotonin syndrome (requires 2-week washout, 5 weeks for fluoxetine); (2) lithium + NSAIDs or diuretics = lithium toxicity; (3) carbamazepine + oral contraceptives = contraceptive failure; (4) fluvoxamine + clozapine = clozapine toxicity; (5) benzodiazepines + alcohol/opioids = respiratory depression. Psychologists must understand these interactions even though they typically do not prescribe, because they assess patient presentation and coordinate with prescribers",
      "id": "PETH-0169"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "The Four Dopamine Pathways",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip The four dopamine pathways explain why antipsychotics have both therapeutic effects (blocking mesolimbic DA reduces positive symptoms) and side effects (blocking nigrostriatal DA causes EPS; blocking tuberoinfundibular DA causes hyperprolactinemia; blocking mesocortical DA may worsen negative/cognitive symptoms). Atypical antipsychotics (e.g., clozapine, quetiapine) produce fewer EPS partly due to their additional 5-HT2A antagonism and looser D2 binding",
      "id": "PETH-0170"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Receptor Subtypes",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip A critical distinction: benzodiazepines are positive allosteric modulators of GABA-A -- they do NOT directly open the chloride channel. They only work when GABA is present, enhancing GABA's own effect. This is why benzodiazepines alone (without other CNS depressants) are relatively safe in overdose. Barbiturates, by contrast, can directly open the chloride channel at high doses even without GABA, which is why barbiturate overdose is much more dangerous",
      "id": "PETH-0171"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Cholinesterase Inhibitors",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Cholinesterase inhibitors provide symptomatic improvement in Alzheimer's disease -- they do not slow or halt disease progression. Their side effects are essentially the opposite of anticholinergic effects (cholinergic excess): nausea, diarrhea, insomnia, vivid dreams, bradycardia. For moderate-to-severe Alzheimer's, memantine (NMDA antagonist) may be added to a cholinesterase inhibitor",
      "id": "PETH-0172"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pediatric Considerations",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip The FDA black box warning on antidepressants and suicidality in youth under 25 is one of the most commonly tested pediatric pharmacology facts on the EPPP. Know that the warning applies to all antidepressants (not just SSRIs), covers patients under age 25 , and refers to suicidal ideation (not completed suicide). Despite this risk, untreated depression also carries suicide risk, and the clinical consensus is that the benefits of antidepressant treatment generally outweigh the risks when properly monitored",
      "id": "PETH-0173"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pregnancy and Teratogenicity",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip The most commonly tested pregnancy pharmacology facts: (1) Valproate is the most teratogenic mood stabilizer (neural tube defects) and is category X; (2) Lithium is associated with Ebstein's anomaly (cardiac) -- know this specific association; (3) Carbamazepine also causes neural tube defects; (4) among antidepressants, paroxetine has the most evidence for cardiac teratogenicity (category D, whereas other SSRIs are category C). Also know that the old A-X system has been replaced by a narrative labeling format (PLLR)",
      "id": "PETH-0174"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacogenomics: Poor vs. Extensive Metabolizers",
      "passage_type": "example",
      "passage": "Example: Pharmacogenomic Testing The FDA has recommended pharmacogenomic testing for certain drug-gene pairs. For example, CYP2D6 genotyping is recommended before prescribing codeine (risk of ultra-rapid metabolism causing morphine toxicity) and CYP2C19 testing can guide citalopram dosing (poor metabolizers require lower doses)",
      "id": "PETH-0175"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Potency vs. Efficacy",
      "passage_type": "example",
      "passage": "Example: Potency vs. Efficacy in Antipsychotics Haloperidol is a high-potency antipsychotic (effective at low doses, e.g., 2-10 mg), while chlorpromazine is a low-potency antipsychotic (requires higher doses, e.g., 200-800 mg). However, at their respective optimal doses, both achieve similar efficacy in treating psychotic symptoms. The key difference lies in their side effect profiles: high-potency agents cause more EPS; low-potency agents cause more sedation, orthostatic hypotension, and anticholinergic effects",
      "id": "PETH-0176"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Receptor Subtypes",
      "passage_type": "example",
      "passage": "Example: Excitotoxicity Excessive glutamate release (e.g., during stroke, traumatic brain injury, or prolonged seizures) causes massive calcium influx through NMDA receptors, triggering a cascade of intracellular events leading to neuronal death. This is the rationale for memantine's neuroprotective effect in Alzheimer's disease -- by partially blocking NMDA receptors, it reduces the damaging effects of chronic, low-level excitotoxicity while still allowing normal synaptic signaling",
      "id": "PETH-0177"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Geriatric Considerations",
      "passage_type": "example",
      "passage": "Example A 78-year-old patient with depression is started on sertraline. Instead of the standard adult starting dose of 50 mg/day, the prescriber starts at 25 mg/day and plans to increase in 25 mg increments every 2-4 weeks as tolerated. The lower starting dose and slower titration reduce the risk of side effects (particularly GI disturbance and hyponatremia/SIADH, which is more common in elderly patients on SSRIs) while the slower titration allows adequate time to assess response given the patient's reduced metabolic capacity",
      "id": "PETH-0178"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Introduction",
      "passage_type": "paragraph",
      "passage": "Before studying individual medication classes, it is essential to understand the foundational principles that govern how drugs work in the body. This chapter covers pharmacokinetics (what the body does to the drug), pharmacodynamics (what the drug does to the body), and the major neurotransmitter systems targeted by psychotropic medications. These concepts underpin every medication chapter that follows and are frequently tested on the EPPP",
      "id": "PETH-0179"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Absorption",
      "passage_type": "paragraph",
      "passage": "Absorption is the process by which a drug enters the bloodstream from its site of administration. For oral medications (the most common route for psychotropics), the drug must dissolve in the GI tract, cross the intestinal epithelium, and enter the portal circulation",
      "id": "PETH-0180"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Distribution",
      "passage_type": "paragraph",
      "passage": "Once absorbed, the drug is distributed throughout the body via the bloodstream. Several factors determine where the drug goes and how much reaches the brain:",
      "id": "PETH-0181"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Metabolism (Biotransformation)",
      "passage_type": "paragraph",
      "passage": "Drug metabolism, primarily occurring in the liver, converts drugs into more water-soluble compounds that can be excreted. Metabolism occurs in two phases:",
      "id": "PETH-0182"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacogenomics: Poor vs. Extensive Metabolizers",
      "passage_type": "paragraph",
      "passage": "Genetic polymorphisms in CYP450 enzymes result in significant variability in how individuals metabolize drugs. This field is known as pharmacogenomics",
      "id": "PETH-0183"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Drug-Receptor Interactions",
      "passage_type": "paragraph",
      "passage": "Most psychotropic medications exert their effects by binding to specific receptors -- protein molecules on cell surfaces or within cells that normally respond to endogenous neurotransmitters or hormones. Key concepts include:",
      "id": "PETH-0184"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Dose-Response Relationships",
      "passage_type": "paragraph",
      "passage": "The relationship between drug dose and the magnitude of effect is described by the dose-response curve . Key parameters include:",
      "id": "PETH-0185"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Therapeutic Index",
      "passage_type": "paragraph",
      "passage": "The therapeutic index (TI) is a critical concept for understanding medication safety. It quantifies the margin between a drug's effective dose and its toxic or lethal dose",
      "id": "PETH-0186"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Narrow Therapeutic Index Drugs",
      "passage_type": "paragraph",
      "passage": "Drugs with a narrow TI have a small margin between the therapeutic and toxic dose. These drugs require careful dosing, blood level monitoring, and vigilance for drug interactions",
      "id": "PETH-0187"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Drug-Drug Interactions",
      "passage_type": "paragraph",
      "passage": "Drug-drug interactions are a major clinical concern and a frequently tested EPPP topic. Interactions can be classified into two broad categories:",
      "id": "PETH-0188"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacodynamic Interactions",
      "passage_type": "paragraph",
      "passage": "These interactions occur when drugs act on the same or related receptor systems, altering the overall pharmacological effect without changing drug concentrations:",
      "id": "PETH-0189"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Major Neurotransmitter Systems",
      "passage_type": "paragraph",
      "passage": "Virtually all psychotropic medications exert their effects by modulating neurotransmitter systems. Understanding the role of each neurotransmitter system -- its brain origins, receptors, and functions -- is essential for understanding why a given medication works for a given disorder, and why it produces specific side effects",
      "id": "PETH-0190"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Anticholinergic Effects",
      "passage_type": "paragraph",
      "passage": "Many psychotropic medications (TCAs, low-potency antipsychotics, antihistamines, some antiparkinsonian drugs) block muscarinic acetylcholine receptors, producing a predictable constellation of side effects:",
      "id": "PETH-0191"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Cholinesterase Inhibitors",
      "passage_type": "paragraph",
      "passage": "Because Alzheimer's disease involves cholinergic neuron degeneration, acetylcholinesterase inhibitors are first-line pharmacotherapy for mild-to-moderate Alzheimer's. They work by inhibiting the enzyme that breaks down ACh, thereby increasing ACh availability at the synapse:",
      "id": "PETH-0192"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Special Populations in Pharmacology",
      "passage_type": "paragraph",
      "passage": "Pharmacological treatment must be adapted for special populations who differ from the typical adult patient in how they absorb, distribute, metabolize, and excrete medications. Understanding these differences is essential for safe prescribing and for psychologists who collaborate with prescribers, assess treatment response, and monitor for adverse effects",
      "id": "PETH-0193"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pediatric Considerations",
      "passage_type": "paragraph",
      "passage": "Children and adolescents are not simply \"small adults\" -- their developing organ systems process medications differently, and they may be more vulnerable to certain side effects",
      "id": "PETH-0194"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Geriatric Considerations",
      "passage_type": "paragraph",
      "passage": "Elderly patients present unique pharmacological challenges due to age-related changes in physiology, increased comorbidities, and polypharmacy",
      "id": "PETH-0195"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pregnancy and Teratogenicity",
      "passage_type": "paragraph",
      "passage": "Prescribing during pregnancy requires careful risk-benefit analysis, weighing the potential teratogenic effects of medications against the risks of untreated mental illness to both the mother and the developing fetus",
      "id": "PETH-0196"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Overview of Standard 4: Privacy and Confidentiality",
      "passage_type": "definition",
      "passage": "Privacy vs. Confidentiality vs. Privilege Privacy is the right of individuals to control access to information about themselves. Confidentiality is the ethical obligation of the psychologist not to disclose information obtained in a professional relationship. Privilege (or testimonial privilege) is a legal right that protects clients from having their confidential communications disclosed in legal proceedings without their consent. Privilege belongs to the client, not the psychologist",
      "id": "PETH-0197"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Tarasoff II (1976) -- Duty to Protect",
      "passage_type": "definition",
      "passage": "Elements Required for Tarasoff Duty Most jurisdictions require: (1) a special relationship exists between the therapist and the dangerous individual (i.e., a treatment relationship); (2) the client makes a credible, serious threat of physical violence; and (3) the threat is directed toward an identifiable potential victim",
      "id": "PETH-0198"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Common Limits of Confidentiality",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip A common EPPP trap: A subpoena alone does NOT require disclosure of confidential records. The psychologist should consult an attorney, notify the client, and may assert privilege on the client's behalf. Only a court order (signed by a judge) compels disclosure. Know this distinction well",
      "id": "PETH-0199"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Psychotherapy Notes Under HIPAA",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip HIPAA psychotherapy notes are ONLY the process notes about the content of therapy sessions, kept separately from the medical record. Treatment plans, diagnoses, and progress notes are NOT psychotherapy notes under HIPAA and can be shared for treatment, payment, and healthcare operations without special authorization",
      "id": "PETH-0200"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Variations Across Jurisdictions",
      "passage_type": "example",
      "passage": "Example A client tells their therapist, \"I'm going to kill my ex-wife when she picks up the kids on Friday.\" This statement involves a serious threat, an identifiable victim, and an apparent timeline. The therapist has a duty to take protective action, which may include warning the ex-wife, contacting police, and potentially seeking involuntary hospitalization for the client",
      "id": "PETH-0201"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Overview of Standard 4: Privacy and Confidentiality",
      "passage_type": "paragraph",
      "passage": "Standard 4 of the APA Ethics Code addresses one of the most fundamental principles of psychological practice: the obligation to protect confidential information obtained through professional work. Confidentiality is central to the therapeutic relationship, as clients must feel safe disclosing sensitive information to benefit from treatment",
      "id": "PETH-0202"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Overview of Standard 4: Privacy and Confidentiality",
      "passage_type": "paragraph",
      "passage": "This standard is one of the most heavily tested on the EPPP. Questions frequently focus on the limits of confidentiality, the duty to warn or protect, HIPAA regulations, and special populations such as minors",
      "id": "PETH-0203"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Standard 4.01: Maintaining Confidentiality",
      "passage_type": "paragraph",
      "passage": "Psychologists have a primary obligation to take reasonable precautions to protect confidential information obtained through or stored in any medium. This includes:",
      "id": "PETH-0204"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Standard 4.01: Maintaining Confidentiality",
      "passage_type": "paragraph",
      "passage": "The duty extends beyond active professional relationships. Psychologists must protect confidential information even after the professional relationship has ended and after the client has died (in most jurisdictions)",
      "id": "PETH-0205"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Standard 4.02: Discussing the Limits of Confidentiality",
      "passage_type": "paragraph",
      "passage": "Psychologists discuss with persons and organizations the relevant limits of confidentiality and the foreseeable uses of information generated through their psychological activities. This discussion should occur:",
      "id": "PETH-0206"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "The Tarasoff Duty: Duty to Warn and Protect",
      "passage_type": "paragraph",
      "passage": "The landmark case Tarasoff v. Regents of the University of California established the legal foundation for the duty to protect third parties from client violence",
      "id": "PETH-0207"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Tarasoff I (1974) -- Duty to Warn",
      "passage_type": "paragraph",
      "passage": "The California Supreme Court initially ruled that therapists have a duty to warn identifiable potential victims when a client communicates a credible threat of violence",
      "id": "PETH-0208"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Tarasoff II (1976) -- Duty to Protect",
      "passage_type": "paragraph",
      "passage": "On rehearing, the court expanded the ruling to establish a broader duty to protect , which may be discharged through various means, not solely by warning the potential victim. Protective actions include:",
      "id": "PETH-0209"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Variations Across Jurisdictions",
      "passage_type": "paragraph",
      "passage": "Not all states have adopted the Tarasoff ruling. Some states have enacted statutes that impose a duty to warn or protect, while others have rejected it entirely. On the EPPP, the general principle tested is awareness that such a duty exists and knowing the basic elements required to trigger it",
      "id": "PETH-0210"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "HIPAA: Health Insurance Portability and Accountability Act",
      "passage_type": "paragraph",
      "passage": "The HIPAA Privacy Rule (2003) established federal standards for protecting individually identifiable health information (Protected Health Information, or PHI). Key provisions for psychologists include:",
      "id": "PETH-0211"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Psychotherapy Notes Under HIPAA",
      "passage_type": "paragraph",
      "passage": "Psychotherapy notes are afforded greater protection than other PHI. Authorization from the client is generally required for disclosure of psychotherapy notes, even to insurance companies. Psychotherapy notes do NOT include:",
      "id": "PETH-0212"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Confidentiality with Minors",
      "passage_type": "paragraph",
      "passage": "Working with minors presents unique confidentiality challenges because the legal right to consent (and access information) typically belongs to the parent or legal guardian, while the therapeutic relationship depends on the minor's trust",
      "id": "PETH-0213"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Confidentiality in Group Therapy",
      "passage_type": "paragraph",
      "passage": "In group therapy, the psychologist cannot guarantee that other group members will maintain confidentiality. The ethical obligation is to:",
      "id": "PETH-0214"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Standard 4.05: Disclosures",
      "passage_type": "paragraph",
      "passage": "Psychologists may disclose confidential information with the appropriate consent of the client or as mandated or permitted by law for valid purposes including:",
      "id": "PETH-0215"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Standard 4.06: Consultations",
      "passage_type": "paragraph",
      "passage": "When consulting with colleagues, psychologists do not disclose confidential information that could reasonably lead to the identification of a client unless they have obtained prior consent or the disclosure cannot be avoided. They share only information necessary for the consultation purpose",
      "id": "PETH-0216"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "The Four D's of Malpractice",
      "passage_type": "definition",
      "passage": "The Four D's 1. Duty: A professional relationship existed, creating a duty of care. 2. Dereliction: The psychologist breached (deviated from) the standard of care. 3. Damage: The client suffered actual harm or injury. 4. Direct causation: The breach of duty directly caused the damage",
      "id": "PETH-0217"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Telepsychology",
      "passage_type": "definition",
      "passage": "PSYPACT The Psychology Interjurisdictional Compact (PSYPACT) is an interstate agreement that allows licensed psychologists in participating states to practice telepsychology and conduct temporary in-person practice across state lines without requiring additional licensure in each state",
      "id": "PETH-0218"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "APA Telepsychology Guidelines (2013)",
      "passage_type": "definition",
      "passage": "Informed Consent for Telehealth Informed consent for telepsychology must address, at minimum: the nature of the service, the technology being used, potential risks to confidentiality (e.g., data breaches, recording), procedures for technology failure, emergency protocols including local resources near the client, whether sessions may be recorded, and the limitations of the technology for the specific type of service being provided",
      "id": "PETH-0219"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Electroconvulsive Therapy (ECT)",
      "passage_type": "definition",
      "passage": "Electroconvulsive Therapy (ECT) ECT involves the administration of a brief, controlled electrical current to the brain under general anesthesia and muscle relaxation, inducing a generalized seizure. Despite its controversial history, ECT remains one of the most effective treatments available for certain severe psychiatric conditions",
      "id": "PETH-0220"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Transcranial Magnetic Stimulation (TMS)",
      "passage_type": "definition",
      "passage": "Transcranial Magnetic Stimulation (TMS) TMS is a non-invasive neuromodulation technique that uses focused magnetic pulses to stimulate or inhibit neural activity in specific brain regions. It does not require anesthesia or sedation, and the patient remains awake and alert throughout the procedure",
      "id": "PETH-0221"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Ketamine and Esketamine",
      "passage_type": "definition",
      "passage": "Ketamine / Esketamine Ketamine is an NMDA receptor antagonist that was originally developed as an anesthetic. It has been found to produce rapid antidepressant effects -- often within hours -- in contrast to traditional antidepressants, which typically require weeks. Esketamine (Spravato) is the S-enantiomer of ketamine, delivered as a nasal spray and FDA-approved for treatment-resistant depression (2019)",
      "id": "PETH-0222"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Common Grounds for Malpractice Claims",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip The most common reason for ethics complaints against psychologists is sexual dual relationships . The most common reason for malpractice payouts varies by source but includes sexual misconduct, failure to warn/protect, and incorrect treatment. Know the Four D's cold -- they appear frequently on the EPPP",
      "id": "PETH-0223"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Typical Licensure Requirements",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Licensure is mandatory and state-regulated ; certification (e.g., ABPP) is voluntary and organization-based . Licensure laws define the scope of practice; certification indicates specialty competence within that scope. State licensing boards have the authority to discipline licensees, including suspending or revoking licenses",
      "id": "PETH-0224"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Social Media Posts by Psychologists",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip The EPPP tests whether you understand that existing ethical principles (confidentiality, boundaries, competence, informed consent) apply to new technologies . No fundamentally new ethical principles are created by social media or telehealth -- rather, familiar principles must be applied to novel contexts. When in doubt on an EPPP question about technology ethics, apply the foundational standards (informed consent, confidentiality, competence, multiple relationships) to the technological scenario",
      "id": "PETH-0225"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Electroconvulsive Therapy (ECT)",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip ECT is the fastest-acting treatment for severe depression and acute suicidality -- faster than any medication. Right unilateral electrode placement with adequate stimulus intensity is the preferred approach when minimizing cognitive side effects is a priority. The most commonly tested ECT fact: retrograde amnesia is the primary cognitive side effect, and bilateral placement causes more memory impairment than right unilateral",
      "id": "PETH-0226"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Legal and Ethical Responsibilities of Supervisors",
      "passage_type": "example",
      "passage": "Example A pre-doctoral intern provides therapy to a suicidal client but does not conduct a formal risk assessment or develop a safety plan. The supervisor does not review the case or ask about high-risk clients. If the client attempts suicide, the supervisor could be held liable under both vicarious liability (for the intern's negligence) and direct liability (for inadequate supervision)",
      "id": "PETH-0227"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Specialty Guidelines for Forensic Psychology",
      "passage_type": "example",
      "passage": "Example A psychologist is asked by an attorney to evaluate a client for competency to stand trial. The psychologist has been providing therapy to this individual for two years. The psychologist should decline the forensic evaluation because serving as both therapist and forensic evaluator creates a dual-role conflict. The psychologist should recommend that an independent forensic evaluator conduct the competency assessment",
      "id": "PETH-0228"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Social Media Boundary Issues",
      "passage_type": "example",
      "passage": "Example A psychologist receives a Facebook friend request from a current therapy client. Accepting the request would create a dual relationship (personal and professional), expose the psychologist's personal life to the client and the client's personal posts to the psychologist, and could inadvertently reveal the therapeutic relationship to mutual connections. The appropriate response is to decline the request and address the issue therapeutically in the next session, discussing boundaries and the rationale for maintaining them",
      "id": "PETH-0229"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Overview of Professional Issues",
      "passage_type": "paragraph",
      "passage": "This chapter covers the legal, regulatory, and professional practice issues that define the practice of psychology. Topics include malpractice liability , supervision models, licensure and credentialing, prescriptive authority, telepsychology, and forensic psychology. These areas are tested on the EPPP because they define the boundaries and responsibilities of professional practice",
      "id": "PETH-0230"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Malpractice and Professional Liability",
      "passage_type": "paragraph",
      "passage": "Malpractice is a form of professional negligence in which a practitioner's conduct falls below the accepted standard of care, resulting in harm to the client. Malpractice claims against psychologists are civil (not criminal) actions",
      "id": "PETH-0231"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Supervision Models and Responsibilities",
      "passage_type": "paragraph",
      "passage": "Clinical supervision is a core competency in professional psychology and carries significant ethical and legal responsibilities",
      "id": "PETH-0232"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Licensure and Certification",
      "passage_type": "paragraph",
      "passage": "Understanding the distinction between licensure, certification, and credentialing is important for both professional practice and the EPPP",
      "id": "PETH-0233"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Scope of Practice",
      "passage_type": "paragraph",
      "passage": "Scope of practice is defined by state statute and describes the range of professional activities a licensed psychologist is legally permitted to perform. Key issues include:",
      "id": "PETH-0234"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Prescriptive Authority",
      "passage_type": "paragraph",
      "passage": "The question of whether psychologists should have the legal authority to prescribe psychotropic medications has been a major professional issue",
      "id": "PETH-0235"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Telepsychology",
      "passage_type": "paragraph",
      "passage": "Telepsychology refers to the provision of psychological services using telecommunication technologies (videoconferencing, telephone, online platforms, mobile apps). Key considerations include:",
      "id": "PETH-0236"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Forensic Psychology Issues",
      "passage_type": "paragraph",
      "passage": "Forensic psychology involves the application of psychological knowledge to legal questions. Forensic psychologists must navigate the tension between the therapeutic role (serving the client's interests) and the forensic role (serving the legal system's interests)",
      "id": "PETH-0237"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Duty to Report Colleague Impairment",
      "passage_type": "paragraph",
      "passage": "When a psychologist becomes aware that a colleague may be impaired (due to substance abuse, mental illness, or personal problems), the first step is typically informal resolution (Standard 1.04) -- speaking directly with the colleague. If the impairment poses a risk of harm to clients and informal resolution is ineffective, reporting to the licensing board or ethics committee may be necessary (Standard 1.05)",
      "id": "PETH-0238"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Termination and Abandonment",
      "passage_type": "paragraph",
      "passage": "Psychologists terminate therapy when it becomes reasonably clear that the client no longer needs the service, is not likely to benefit, or is being harmed. Except where precluded by the actions of the client, the psychologist provides pretermination counseling and suggests alternative service providers as appropriate. Abrupt termination without reasonable notice and referral options may constitute abandonment",
      "id": "PETH-0239"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Social Media and Electronic Communications Ethics",
      "passage_type": "paragraph",
      "passage": "The rapid expansion of digital technology has introduced new ethical challenges for psychologists. Social media , email, text messaging, online therapy platforms, and other electronic communications create novel boundary, confidentiality, and competence issues that psychologists must navigate carefully",
      "id": "PETH-0240"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "APA Telepsychology Guidelines (2013)",
      "passage_type": "paragraph",
      "passage": "The APA published the Guidelines for the Practice of Telepsychology in 2013, providing a framework for the ethical delivery of psychological services via telecommunication technologies. Key principles include:",
      "id": "PETH-0241"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Social Media Boundary Issues",
      "passage_type": "paragraph",
      "passage": "Social media has blurred the boundaries between the personal and professional lives of psychologists. Key ethical considerations include:",
      "id": "PETH-0242"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Online Therapy Platforms and HIPAA Compliance",
      "passage_type": "paragraph",
      "passage": "The proliferation of online therapy platforms (e.g., video-based telehealth services) has increased access to mental health care but also introduces compliance requirements:",
      "id": "PETH-0243"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Digital Native vs. Digital Immigrant Considerations",
      "passage_type": "paragraph",
      "passage": "The distinction between digital natives (individuals who grew up with digital technology) and digital immigrants (individuals who adopted technology later in life) is relevant to both service delivery and competence:",
      "id": "PETH-0244"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Novel and Emerging Treatments",
      "passage_type": "paragraph",
      "passage": "Several non-traditional biological treatments have become increasingly important in the treatment of psychiatric disorders. Psychologists -- even those who do not prescribe -- are expected to understand these treatments because they assess patient response, collaborate with prescribers, and may be asked about them by clients. These topics are appearing with increasing frequency on the EPPP",
      "id": "PETH-0245"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Psychedelic-Assisted Therapy",
      "passage_type": "paragraph",
      "passage": "Research on psychedelic-assisted therapy has re-emerged as a significant area of psychiatric treatment research. Key developments include:",
      "id": "PETH-0246"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "6.03: Withholding Records for Nonpayment",
      "passage_type": "definition",
      "passage": "Key Rule In a non-emergency situation, psychologists may have legal grounds to withhold records for nonpayment, depending on state law. But in an emergency , records needed for treatment must be provided regardless of payment status. The EPPP frequently tests this distinction",
      "id": "PETH-0247"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "6.05: Bartering with Clients",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip The APA Ethics Code does NOT prohibit bartering outright. It allows bartering when it is not exploitative and not clinically contraindicated. This is a nuanced position -- many EPPP questions test whether you know that bartering is permissible under the right conditions, especially in rural or underserved communities where financial options may be limited",
      "id": "PETH-0248"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "6.05: Bartering with Clients",
      "passage_type": "example",
      "passage": "Example A client who is a carpenter offers to build bookshelves for the psychologist's office in exchange for therapy sessions. This arrangement may be acceptable if: (a) the exchange is fair and agreed upon by both parties, (b) there is no power imbalance that could lead to exploitation, and (c) the arrangement is not clinically contraindicated (e.g., the client is not in treatment for issues related to self-worth or financial dependency). The psychologist should document the arrangement and consult with a colleague",
      "id": "PETH-0249"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "Overview of Standard 6: Record Keeping and Fees",
      "passage_type": "paragraph",
      "passage": "Standard 6 (Record Keeping and Fees) of the APA Ethics Code covers documentation practices, fee arrangements, bartering, and billing accuracy. These provisions protect both clients and the integrity of the profession by ensuring transparent financial dealings and proper record management",
      "id": "PETH-0250"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "Overview of Standard 6: Record Keeping and Fees",
      "passage_type": "paragraph",
      "passage": "Standard 6 is tested on the EPPP because fee-related ethical violations can directly exploit clients and damage the therapeutic relationship",
      "id": "PETH-0251"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "6.01: Documentation of Professional and Scientific Work",
      "passage_type": "paragraph",
      "passage": "Psychologists create and maintain documentation in sufficient detail to facilitate provision of services later by themselves or other professionals, to allow for replication of research design and analysis, to meet institutional requirements, to ensure accuracy of billing and payments, and to ensure compliance with law",
      "id": "PETH-0252"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "6.02: Maintenance, Dissemination, and Disposal of Records",
      "passage_type": "paragraph",
      "passage": "Psychologists maintain confidentiality in creating, storing, accessing, transferring, and disposing of records. They are responsible for:",
      "id": "PETH-0253"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "6.03: Withholding Records for Nonpayment",
      "passage_type": "paragraph",
      "passage": "Psychologists may not withhold records under their control that are requested and needed for a client's emergency treatment solely because payment has not been received. This provision prioritizes client welfare over financial considerations in emergency situations",
      "id": "PETH-0254"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "6.04: Fees and Financial Arrangements",
      "passage_type": "paragraph",
      "passage": "As early as feasible in a professional or scientific relationship, psychologists and recipients of psychological services reach an agreement specifying compensation and billing arrangements. Fee agreements should include:",
      "id": "PETH-0255"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "6.04: Fees and Financial Arrangements",
      "passage_type": "paragraph",
      "passage": "Psychologists do not misrepresent their fees. If limitations to services can be anticipated because of limitations in financing, this is discussed with the client as early as feasible",
      "id": "PETH-0256"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "6.05: Bartering with Clients",
      "passage_type": "paragraph",
      "passage": "Bartering is the acceptance of goods, services, or other nonmonetary remuneration from clients in return for psychological services. Psychologists may barter only if:",
      "id": "PETH-0257"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "6.06: Accuracy in Reports to Payors and Funding Sources",
      "passage_type": "paragraph",
      "passage": "Psychologists take reasonable steps to ensure the accurate reporting of the nature of the service provided, the fees, charges, or payments, and where applicable, the identity of the provider, the findings, and the diagnosis. They do not knowingly make fraudulent claims, which includes:",
      "id": "PETH-0258"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "6.07: Referrals and Fees",
      "passage_type": "paragraph",
      "passage": "When psychologists pay, receive payment from, or divide fees with another professional, the payment must be based on the services provided (clinical, consultative, administrative, or other) and is not based on the referral itself. Psychologists do not receive or pay referral fees (also called fee splitting or kickbacks) simply for sending or receiving client referrals",
      "id": "PETH-0259"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.01: Institutional Approval (IRB)",
      "passage_type": "definition",
      "passage": "Institutional Review Board (IRB) An IRB is a committee established to review and approve research involving human subjects. IRBs evaluate proposals based on three levels of review: exempt (minimal risk, no identifying information), expedited (minimal risk but involves identifiable data), and full board review (greater than minimal risk). The IRB ensures compliance with the Belmont Report principles of respect for persons, beneficence, and justice",
      "id": "PETH-0260"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.12: Publication Credit (Authorship)",
      "passage_type": "definition",
      "passage": "Authorship Rules Mere possession of an institutional position (e.g., department chair) does not justify authorship credit. Minor contributions to research or writing are acknowledged in footnotes or an introductory statement. A student is listed as principal author on any multiple-authored article that is substantially based on the student's doctoral dissertation",
      "id": "PETH-0261"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.08: Debriefing",
      "passage_type": "example",
      "passage": "Example In a study on obedience, participants are told they are administering electric shocks to another participant (who is actually a confederate receiving no shocks). This involves deception about the true purpose and nature of the study. After the study, the researcher must debrief participants immediately, explain the deception, reassure them no one was harmed, and monitor for any psychological distress. Participants must be offered the opportunity to withdraw their data",
      "id": "PETH-0262"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "Overview of Standard 8: Research and Publication",
      "passage_type": "paragraph",
      "passage": "Standard 8 (Research and Publication) of the APA Ethics Code covers ethical requirements for conducting research, including IRB approval, informed consent, use of deception, debriefing, animal research, and publication practices. This standard ensures the protection of research participants and the integrity of scientific knowledge",
      "id": "PETH-0263"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "Overview of Standard 8: Research and Publication",
      "passage_type": "paragraph",
      "passage": "Research ethics is heavily tested on the EPPP, with frequent questions about the Belmont Report, deception in research, debriefing requirements, and authorship credit",
      "id": "PETH-0264"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.01: Institutional Approval (IRB)",
      "passage_type": "paragraph",
      "passage": "When institutional approval is required, psychologists provide accurate information about their research proposals and obtain approval prior to conducting the research. They conduct the research in accordance with the approved protocol",
      "id": "PETH-0265"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.03: Informed Consent for Recording",
      "passage_type": "paragraph",
      "passage": "Psychologists obtain informed consent before recording voices or images of individuals for data collection, unless: (a) the research consists solely of naturalistic observation in public places with no anticipated personal identification or harm, or (b) the research design includes deception and consent for the use of the recording is obtained during debriefing",
      "id": "PETH-0266"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.04: Client/Patient, Student, and Subordinate Research Participants",
      "passage_type": "paragraph",
      "passage": "When psychologists conduct research with clients, students, or subordinates as participants, they take steps to protect prospective participants from adverse consequences of declining or withdrawing. When research participation is a course requirement or opportunity for extra credit, prospective participants must be given equitable alternative activities",
      "id": "PETH-0267"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.06: Offering Inducements for Research Participation",
      "passage_type": "paragraph",
      "passage": "Psychologists make reasonable efforts to avoid offering excessive or inappropriate financial or other inducements for research participation when such inducements could be coercive. This is especially important when participants are economically disadvantaged or otherwise vulnerable",
      "id": "PETH-0268"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.07: Deception in Research",
      "passage_type": "paragraph",
      "passage": "Any deception must be explained to participants as early as feasible, preferably at the conclusion of their participation but no later than at the conclusion of the data collection. Participants must be permitted to withdraw their data",
      "id": "PETH-0269"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.08: Debriefing",
      "passage_type": "paragraph",
      "passage": "Psychologists provide participants with a prompt opportunity to obtain appropriate information about the study, including:",
      "id": "PETH-0270"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.08: Debriefing",
      "passage_type": "paragraph",
      "passage": "If scientific or humane values justify delaying or withholding debriefing information, psychologists take reasonable measures to reduce the risk of harm. When psychologists become aware that research procedures have harmed a participant, they take reasonable steps to minimize the harm",
      "id": "PETH-0271"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.10: Reporting Research Results",
      "passage_type": "paragraph",
      "passage": "Psychologists do not fabricate data. If they discover significant errors in published data, they take reasonable steps to correct such errors through correction, retraction, erratum, or other appropriate publication means",
      "id": "PETH-0272"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.11: Plagiarism",
      "passage_type": "paragraph",
      "passage": "Psychologists do not present portions of another's work or data as their own, even if the other work or data source is cited occasionally",
      "id": "PETH-0273"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.12: Publication Credit (Authorship)",
      "passage_type": "paragraph",
      "passage": "Psychologists take responsibility and credit, including authorship credit, only for work they have actually performed or to which they have substantially contributed. Principal authorship and other publication credits accurately reflect the relative scientific or professional contributions of the individuals involved",
      "id": "PETH-0274"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.13: Duplicate Publication of Data",
      "passage_type": "paragraph",
      "passage": "Psychologists do not publish, as original data, data that have been previously published. This does not preclude republishing data when they are accompanied by proper acknowledgment",
      "id": "PETH-0275"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.14: Sharing Research Data for Verification",
      "passage_type": "paragraph",
      "passage": "After research results are published, psychologists do not withhold the data on which their conclusions are based from other competent professionals who seek to verify the substantive claims through reanalysis, provided that the confidentiality of participants can be protected and legal rights concerning proprietary data do not preclude their release",
      "id": "PETH-0276"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "1.04 Informal Resolution of Ethical Violations",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip On the EPPP, when asked \"what should a psychologist do first?\" upon learning a colleague may be acting unethically, the answer is usually to attempt informal resolution (1.04) -- UNLESS doing so would violate confidentiality or the violation is too serious for informal resolution (e.g., sexual contact with a client)",
      "id": "PETH-0277"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "1.02 Conflicts Between Ethics and Law, Regulations, or Other Governing Legal Authority",
      "passage_type": "example",
      "passage": "Example A psychologist working in a correctional facility is ordered by administration to provide confidential therapy records to correctional officers. This conflicts with Standard 4 (Confidentiality). Under 1.02, the psychologist should clarify the conflict, advocate for confidentiality, and try to resolve the situation -- but cannot simply ignore the legal authority without taking constructive action",
      "id": "PETH-0278"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "Overview: Resolving Ethical Issues",
      "passage_type": "paragraph",
      "passage": "Standard 1 of the APA Ethics Code addresses what psychologists should do when they encounter ethical problems, conflicts between ethics and law or organizational demands, or knowledge of others' ethical violations. This standard is foundational because it provides the framework for addressing ethical dilemmas that arise in all areas of professional practice",
      "id": "PETH-0279"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "Overview: Resolving Ethical Issues",
      "passage_type": "paragraph",
      "passage": "Standard 1 is frequently tested on the EPPP because ethical conflicts are inherent in professional psychology, and knowing the proper steps for resolving them is essential",
      "id": "PETH-0280"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "Standard 1: Resolving Ethical Issues",
      "passage_type": "paragraph",
      "passage": "Standard 1 addresses what psychologists should do when they encounter ethical problems, conflicts between ethics and law, or knowledge of others' ethical violations",
      "id": "PETH-0281"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "1.01 Misuse of Psychologists' Work",
      "passage_type": "paragraph",
      "passage": "If psychologists learn that their work is being misused or misrepresented by others, they take reasonable steps to correct or minimize the misuse or misrepresentation",
      "id": "PETH-0282"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "1.02 Conflicts Between Ethics and Law, Regulations, or Other Governing Legal Authority",
      "passage_type": "paragraph",
      "passage": "If psychologists' ethical responsibilities conflict with law, regulations, or other governing legal authority, psychologists clarify the nature of the conflict, make known their commitment to the Ethics Code, and take reasonable steps to resolve the conflict consistent with the General Principles and Ethical Standards. Under no circumstances does this standard allow a psychologist to violate human rights",
      "id": "PETH-0283"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "1.03 Conflicts Between Ethics and Organizational Demands",
      "passage_type": "paragraph",
      "passage": "If the demands of an organization with which psychologists are affiliated conflict with the Ethics Code, they clarify the nature of the conflict, make known their commitment to the Ethics Code, and take reasonable steps to resolve the conflict. If the conflict is unresolvable, the psychologist may adhere to the requirements of law, regulations, or other governing legal authority",
      "id": "PETH-0284"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "1.04 Informal Resolution of Ethical Violations",
      "passage_type": "paragraph",
      "passage": "When psychologists believe there has been an ethical violation by another psychologist, they attempt to resolve the issue by bringing it to the attention of that individual, if an informal resolution appears appropriate and the intervention does not violate any confidentiality rights",
      "id": "PETH-0285"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "1.05 Reporting Ethical Violations",
      "passage_type": "paragraph",
      "passage": "If an apparent ethical violation has substantially harmed or is likely to substantially harm a person or organization and is not appropriate for informal resolution, psychologists take further action such as referral to state or national ethics committees or licensing boards. This standard does not apply when an intervention would violate confidentiality rights or when psychologists have been retained to review the work of another psychologist whose professional conduct is in question",
      "id": "PETH-0286"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "1.06 Cooperating with Ethics Committees",
      "passage_type": "paragraph",
      "passage": "Psychologists cooperate in ethics investigations, proceedings, and resulting requirements of the APA or any affiliated state psychological association to which they belong. Failure to cooperate is itself an ethics violation",
      "id": "PETH-0287"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "1.07 Improper Complaints",
      "passage_type": "paragraph",
      "passage": "Psychologists do not file or encourage the filing of ethics complaints that are made with reckless disregard for or willful ignorance of facts that would disprove the allegation",
      "id": "PETH-0288"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "1.08 Unfair Discrimination Against Complainants and Respondents",
      "passage_type": "paragraph",
      "passage": "Psychologists do not deny persons employment, advancement, admissions, or other benefits solely because they have made or been the subject of an ethics complaint. This does not preclude taking action based on the outcome of such proceedings",
      "id": "PETH-0289"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "stimulants-adhd.html",
      "chapter_title": "Stimulants & ADHD Meds",
      "section": "Psychostimulants",
      "passage_type": "paragraph",
      "passage": "Stimulant medications are the first-line pharmacological treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) . They work by increasing dopamine and norepinephrine activity in the prefrontal cortex",
      "id": "PETH-0290"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.03: Group Therapy",
      "passage_type": "definition",
      "passage": "Key Point In group therapy, the therapist's ethical obligation to confidentiality applies to the therapist, but the therapist cannot compel other group members to keep information confidential. This limitation must be disclosed to all group members at the outset",
      "id": "PETH-0291"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.07: Therapy with Former Sexual Partners",
      "passage_type": "definition",
      "passage": "Key Distinction Standard 10.07 addresses the direction from sexual partner to therapy client (always prohibited). Standard 10.08 addresses the direction from therapy client to sexual partner (prohibited for at least two years, and rarely appropriate even after). Both reflect the permanent power imbalance created by the therapeutic relationship",
      "id": "PETH-0292"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "10.01(c) -- Individuals Lacking Capacity",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Informed consent is not a one-time event but an ongoing process. As therapy progresses and circumstances change (e.g., switching from individual to couples therapy, adding a new treatment modality), informed consent should be revisited",
      "id": "PETH-0293"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.04: Providing Therapy to Those Served by Others",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip This standard does not prohibit providing services to someone already in treatment elsewhere -- it requires careful consideration. If a client is seeing another therapist, the new psychologist should discuss potential issues (e.g., conflicting treatment approaches), consider consulting with the other provider (with appropriate consent), and proceed carefully",
      "id": "PETH-0294"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.08: Sexual Intimacies with Former Therapy Clients",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip The two-year rule (10.08) is one of the most tested facts on the EPPP. Key points: (1) The two-year clock starts at termination, not at the beginning of therapy. (2) Even after two years, sexual contact is permitted only in the \"most unusual circumstances.\" (3) The burden of proof falls entirely on the psychologist. (4) Most ethics scholars advise that sexual relationships with former clients should always be avoided",
      "id": "PETH-0295"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "10.10(c) -- Threats and Relationships",
      "passage_type": "clinical_note",
      "passage": "EPPP Tip Termination is appropriate when: (1) the client has met treatment goals, (2) the client is no longer benefiting, (3) continued treatment could cause harm, or (4) the therapist is endangered. Abandonment -- abruptly discontinuing services without appropriate notice and referral -- is an ethical violation. Even when a client refuses to pay, the psychologist should make reasonable efforts to provide pretermination counseling and referrals",
      "id": "PETH-0296"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.02: Therapy Involving Couples or Families",
      "passage_type": "example",
      "passage": "Example A psychologist providing couples therapy learns that one partner wants to file for divorce and asks the psychologist to testify about the other partner's mental health. The psychologist should clarify that their role as couples therapist is incompatible with serving as a forensic evaluator or witness for one party. The psychologist should decline the forensic role and may need to discuss whether continuing couples therapy is appropriate",
      "id": "PETH-0297"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "10.10(c) -- Threats and Relationships",
      "passage_type": "example",
      "passage": "Example A psychologist's client has met their treatment goals and has been stable for several months. The psychologist discusses the client's progress, proposes termination, and works with the client to develop a plan for maintaining gains. The psychologist provides referral information in case the client needs services in the future. This is an example of appropriate, planned termination",
      "id": "PETH-0298"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Overview of Standard 10: Therapy",
      "passage_type": "paragraph",
      "passage": "Standard 10 of the APA Ethics Code governs the ethical conduct of psychotherapy and counseling relationships. This standard covers informed consent to therapy, specialized treatment contexts (couples, families, groups), restrictions on providing therapy to those already receiving services elsewhere, sexual boundaries, and the appropriate interruption and termination of therapy",
      "id": "PETH-0299"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Overview of Standard 10: Therapy",
      "passage_type": "paragraph",
      "passage": "Standard 10 is one of the most heavily tested areas on the EPPP because therapy relationships involve significant power differentials and intimate disclosures that create particular vulnerability for clients",
      "id": "PETH-0300"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "10.01(a) -- General Requirements",
      "passage_type": "paragraph",
      "passage": "When obtaining informed consent to therapy, psychologists inform clients as early as is feasible in the therapeutic relationship about:",
      "id": "PETH-0301"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "10.01(b) -- Scientifically Unvalidated Treatments",
      "passage_type": "paragraph",
      "passage": "When the therapist's technique or approach is substantially unvalidated or still developing, the psychologist must inform the client of the developing nature of the treatment, the potential risks involved, and available alternative treatments that may be effective",
      "id": "PETH-0302"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "10.01(c) -- Individuals Lacking Capacity",
      "passage_type": "paragraph",
      "passage": "When the person receiving therapy is legally incapable of giving informed consent (e.g., a minor or an individual adjudicated incompetent), the psychologist provides an appropriate explanation, seeks the individual's assent, considers the person's preferences and best interests, and obtains appropriate permission from a legally authorized person",
      "id": "PETH-0303"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.02: Therapy Involving Couples or Families",
      "passage_type": "paragraph",
      "passage": "When a psychologist agrees to provide services to several persons who have a relationship (such as spouses, significant others, or parents and children), the psychologist takes reasonable steps to clarify at the outset:",
      "id": "PETH-0304"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.02: Therapy Involving Couples or Families",
      "passage_type": "paragraph",
      "passage": "If it becomes apparent that the psychologist may be called on to perform potentially conflicting roles (such as family therapist and then witness for one party in divorce proceedings), the psychologist takes reasonable steps to clarify and modify, or withdraw from, roles as appropriate",
      "id": "PETH-0305"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.03: Group Therapy",
      "passage_type": "paragraph",
      "passage": "When psychologists provide services to several persons in a group setting, they describe at the outset the roles and responsibilities of all parties and the limits of confidentiality. The psychologist must explain that while the psychologist is bound by confidentiality, other group members are not and the psychologist cannot guarantee that group members will maintain each other's confidentiality",
      "id": "PETH-0306"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.04: Providing Therapy to Those Served by Others",
      "passage_type": "paragraph",
      "passage": "In deciding whether to offer or provide services to those already receiving mental health services elsewhere, psychologists carefully consider the treatment issues and the potential client's welfare. The psychologist discusses these issues with the client, or another legally authorized person on behalf of the client, to minimize the risk of confusion and conflict, consults with the other service providers when appropriate, and proceeds with caution and sensitivity to the therapeutic issues",
      "id": "PETH-0307"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.05: Sexual Intimacies with Current Therapy Clients/Patients",
      "passage_type": "paragraph",
      "passage": "Psychologists do not engage in sexual intimacies with current therapy clients/patients. This prohibition is absolute -- there are no exceptions, regardless of the client's age, consent, or the nature of the therapeutic relationship",
      "id": "PETH-0308"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.05: Sexual Intimacies with Current Therapy Clients/Patients",
      "passage_type": "paragraph",
      "passage": "Sexual intimacies include sexual intercourse, sexual contact, and other behaviors of a sexual nature. This standard applies regardless of who initiates the sexual contact",
      "id": "PETH-0309"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.06: Sexual Intimacies with Relatives or Significant Others of Current Clients",
      "passage_type": "paragraph",
      "passage": "Psychologists do not engage in sexual intimacies with individuals they know to be close relatives, guardians, or significant others of current clients/patients. This prohibition recognizes that sexual contact with a client's family member or partner could seriously harm the client and compromise the therapeutic relationship",
      "id": "PETH-0310"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.07: Therapy with Former Sexual Partners",
      "passage_type": "paragraph",
      "passage": "Psychologists do not accept as therapy clients/patients persons with whom they have engaged in sexual intimacies. This prohibition is absolute and permanent -- there is no time limit or exception. If a psychologist has had a sexual relationship with someone, that person may never become the psychologist's therapy client",
      "id": "PETH-0311"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.08: Sexual Intimacies with Former Therapy Clients",
      "passage_type": "paragraph",
      "passage": "Psychologists do not engage in sexual intimacies with former clients/patients for at least two years after cessation or termination of therapy",
      "id": "PETH-0312"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.08: Sexual Intimacies with Former Therapy Clients",
      "passage_type": "paragraph",
      "passage": "Even after two years, psychologists do not engage in sexual intimacies with former clients except in the most unusual circumstances . The psychologist who engages in such activity bears the burden of demonstrating that there has been no exploitation, in light of all relevant factors, including:",
      "id": "PETH-0313"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.09: Interruption of Therapy",
      "passage_type": "paragraph",
      "passage": "When entering into employment or contractual relationships, psychologists make reasonable efforts to provide for orderly and appropriate resolution of responsibility for client/patient care in the event that the employment or contractual relationship ends, with paramount consideration given to the welfare of the client/patient",
      "id": "PETH-0314"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.09: Interruption of Therapy",
      "passage_type": "paragraph",
      "passage": "Psychologists should plan for potential disruptions in service (e.g., illness, relocation, organizational changes) and ensure that clients can continue to receive appropriate care",
      "id": "PETH-0315"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "10.10(a) -- When to Terminate",
      "passage_type": "paragraph",
      "passage": "Psychologists terminate therapy when it becomes reasonably clear that the client/patient no longer needs the service, is not likely to benefit, or is being harmed by continued service",
      "id": "PETH-0316"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "10.10(b) -- Pretermination Counseling",
      "passage_type": "paragraph",
      "passage": "Except where precluded by the actions of clients/patients or third-party payors, psychologists provide pretermination counseling and suggest alternative service providers as appropriate prior to termination",
      "id": "PETH-0317"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "10.10(c) -- Threats and Relationships",
      "passage_type": "paragraph",
      "passage": "Psychologists may terminate therapy when threatened or otherwise endangered by the client/patient or another person with whom the client/patient has a relationship",
      "id": "PETH-0318"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "5.02: Statements by Others",
      "passage_type": "paragraph",
      "passage": "Psychologists do not compensate employees of press, radio, television, or other communication media in return for publicity in a news item.",
      "id": "PETH-0319"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "All public statements must be truthful and non-deceptive -- psychologists cannot claim unsubstantiated success rates, misleading credentials, or false affiliations.",
      "id": "PETH-0320"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Psychologists retain responsibility for statements made by others on their behalf (Standard 5.02).",
      "id": "PETH-0321"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Testimonials may not be solicited from current therapy clients or others vulnerable to undue influence.",
      "id": "PETH-0322"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "In-person solicitation of vulnerable individuals is prohibited, but general marketing is permissible.",
      "id": "PETH-0323"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Workshop and program descriptions must accurately represent objectives, presenters, fees, and prerequisites.",
      "id": "PETH-0324"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "advertising.html",
      "chapter_title": "Advertising & Public Statements (Std 5)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Media presentations must be based on appropriate literature and must not imply a professional relationship with the audience.",
      "id": "PETH-0325"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Common Side Effects of SSRIs",
      "passage_type": "paragraph",
      "passage": "Sexual dysfunction (decreased libido, anorgasmia, erectile dysfunction) -- most common reason for discontinuation",
      "id": "PETH-0326"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Common Side Effects of SSRIs",
      "passage_type": "paragraph",
      "passage": "Discontinuation syndrome with abrupt cessation (dizziness, nausea, \"brain zaps,\" irritability)",
      "id": "PETH-0327"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Side Effects of SNRIs",
      "passage_type": "paragraph",
      "passage": "Elevated blood pressure (especially venlafaxine at higher doses) -- blood pressure monitoring recommended",
      "id": "PETH-0328"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Side Effects of SNRIs",
      "passage_type": "paragraph",
      "passage": "Discontinuation syndrome (particularly severe with venlafaxine due to its short half-life)",
      "id": "PETH-0329"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Side Effects of TCAs",
      "passage_type": "paragraph",
      "passage": "Anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision, tachycardia) -- remember \"can't see, can't pee, can't spit, can't sh*t\"",
      "id": "PETH-0330"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Side Effects of TCAs",
      "passage_type": "paragraph",
      "passage": "Cardiac toxicity -- fatal in overdose due to cardiac arrhythmias (QT prolongation, heart block). This is why TCAs are dangerous in suicidal patients.",
      "id": "PETH-0331"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Mechanism of Action",
      "passage_type": "paragraph",
      "passage": "MAO-B preferentially metabolizes dopamine (selegiline, used in Parkinson's disease, is selective for MAO-B at low doses)",
      "id": "PETH-0332"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Common MAOIs",
      "passage_type": "paragraph",
      "passage": "Selegiline (Emsam) -- available as a transdermal patch; at low doses, selective for MAO-B; dietary restrictions may not be required at lowest patch dose",
      "id": "PETH-0333"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "The Tyramine Crisis (Hypertensive Crisis)",
      "passage_type": "paragraph",
      "passage": "Certain dietary supplements and over-the-counter cold medications containing pseudoephedrine or phenylephrine",
      "id": "PETH-0334"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Bupropion (Wellbutrin)",
      "passage_type": "paragraph",
      "passage": "Mechanism: Norepinephrine-dopamine reuptake inhibitor (NDRI); does NOT affect serotonin",
      "id": "PETH-0335"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Bupropion (Wellbutrin)",
      "passage_type": "paragraph",
      "passage": "Advantages: No sexual dysfunction (may actually improve libido); no weight gain (may cause weight loss); activating rather than sedating",
      "id": "PETH-0336"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Bupropion (Wellbutrin)",
      "passage_type": "paragraph",
      "passage": "Risks: Lowers seizure threshold (contraindicated in patients with seizure disorders, eating disorders, or those undergoing abrupt alcohol withdrawal); may increase anxiety",
      "id": "PETH-0337"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Mirtazapine (Remeron)",
      "passage_type": "paragraph",
      "passage": "Mechanism: Noradrenergic and specific serotonergic antidepressant (NaSSA); blocks alpha-2 autoreceptors (increasing NE and 5-HT release) and 5-HT2 and 5-HT3 receptors; potent H1 antagonist",
      "id": "PETH-0338"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Mirtazapine (Remeron)",
      "passage_type": "paragraph",
      "passage": "Side effects: Significant sedation and weight gain (due to H1 blockade); increased appetite; useful when these \"side effects\" are actually therapeutic goals",
      "id": "PETH-0339"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Trazodone (Desyrel)",
      "passage_type": "paragraph",
      "passage": "Uses: Primarily used as a sleep aid at low doses; antidepressant at higher doses (rarely used this way due to sedation)",
      "id": "PETH-0340"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Trazodone (Desyrel)",
      "passage_type": "paragraph",
      "passage": "Side effects: Sedation, orthostatic hypotension, priapism (rare but serious -- prolonged painful erection requiring emergency treatment)",
      "id": "PETH-0341"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Clinical Triad of Serotonin Syndrome",
      "passage_type": "paragraph",
      "passage": "Autonomic instability: Hyperthermia, tachycardia, diaphoresis (sweating), diarrhea, fluctuating blood pressure",
      "id": "PETH-0342"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Clinical Triad of Serotonin Syndrome",
      "passage_type": "paragraph",
      "passage": "Neuromuscular abnormalities: Tremor, myoclonus (muscle jerking), hyperreflexia, rigidity, clonus",
      "id": "PETH-0343"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "The FDA Black Box Warning",
      "passage_type": "paragraph",
      "passage": "The risk appears to be highest during the first 1-2 months of treatment or after dose changes",
      "id": "PETH-0344"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "The FDA Black Box Warning",
      "passage_type": "paragraph",
      "passage": "The mechanism is thought to involve an initial increase in energy and motivation before mood fully improves, potentially enabling a suicidal individual to act on preexisting ideation",
      "id": "PETH-0345"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "The FDA Black Box Warning",
      "passage_type": "paragraph",
      "passage": "Close monitoring is recommended during the initial period of treatment, especially in young patients",
      "id": "PETH-0346"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "The FDA Black Box Warning",
      "passage_type": "paragraph",
      "passage": "The warning does NOT state that antidepressants should not be prescribed to young people; the benefits generally outweigh the risks, but careful monitoring is essential",
      "id": "PETH-0347"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "SSRIs are first-line treatment for depression and anxiety; primary side effects include sexual dysfunction and GI disturbance.",
      "id": "PETH-0348"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Fluoxetine has the longest half-life and is the only SSRI FDA-approved for pediatric depression.",
      "id": "PETH-0349"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "SNRIs block both serotonin and norepinephrine reuptake; venlafaxine can raise blood pressure.",
      "id": "PETH-0350"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "TCAs are lethal in overdose due to cardiac arrhythmias; cause anticholinergic side effects and sedation.",
      "id": "PETH-0351"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Clomipramine is the most serotonergic TCA and the first-line pharmacotherapy for OCD.",
      "id": "PETH-0352"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "MAOIs require strict dietary restrictions to avoid tyramine-induced hypertensive crisis; require a 2-week washout before switching to serotonergic drugs.",
      "id": "PETH-0353"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Bupropion (NDRI) does not cause sexual dysfunction, aids in smoking cessation, but lowers seizure threshold.",
      "id": "PETH-0354"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Mirtazapine causes sedation and weight gain but no sexual dysfunction; useful when appetite stimulation and sleep are needed.",
      "id": "PETH-0355"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Serotonin syndrome results from combining serotonergic agents and presents with the triad of cognitive changes, autonomic instability, and neuromuscular hyperactivity.",
      "id": "PETH-0356"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "The FDA black box warning applies to suicidality risk in patients aged 24 and under during initial antidepressant treatment.",
      "id": "PETH-0357"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "The Tyramine Crisis (Hypertensive Crisis)",
      "passage_type": "paragraph",
      "passage": "Foods to avoid while taking MAOIs include:",
      "id": "PETH-0358"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antidepressants.html",
      "chapter_title": "Antidepressants",
      "section": "Atypical Antidepressants",
      "passage_type": "paragraph",
      "passage": "Several antidepressants do not fit neatly into the above categories and are classified as atypical antidepressants.",
      "id": "PETH-0359"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "The Dopamine Hypothesis of Schizophrenia",
      "passage_type": "paragraph",
      "passage": "Positive symptoms (hallucinations, delusions, disorganized thought) are associated with excess dopamine activity in the mesolimbic pathway",
      "id": "PETH-0360"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "The Dopamine Hypothesis of Schizophrenia",
      "passage_type": "paragraph",
      "passage": "Negative symptoms (flat affect, avolition, alogia, anhedonia) are associated with reduced dopamine activity in the mesocortical pathway (prefrontal cortex)",
      "id": "PETH-0361"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Clinical Features of NMS (mnemonic: FEVER)",
      "passage_type": "paragraph",
      "passage": "Vitals unstable (autonomic instability: tachycardia, labile blood pressure, diaphoresis)",
      "id": "PETH-0362"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Typical antipsychotics work via D2 blockade; atypicals combine D2 and 5-HT2A blockade.",
      "id": "PETH-0363"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "High-potency typicals (haloperidol) = high EPS risk, low sedation. Low-potency typicals (chlorpromazine) = low EPS risk, high sedation.",
      "id": "PETH-0364"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "EPS timeline: acute dystonia (hours-days), akathisia (days-weeks), parkinsonism (weeks-months), tardive dyskinesia (months-years).",
      "id": "PETH-0365"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "NMS is a medical emergency: hyperthermia, lead-pipe rigidity, autonomic instability, elevated CPK. Treat with dantrolene and bromocriptine.",
      "id": "PETH-0366"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Clozapine is the gold standard for treatment-resistant schizophrenia but requires blood monitoring for agranulocytosis.",
      "id": "PETH-0367"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Metabolic monitoring is recommended for all patients on atypical antipsychotics.",
      "id": "PETH-0368"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Tardive dyskinesia may be irreversible and can worsen when the offending drug is stopped.",
      "id": "PETH-0369"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "The Dopamine Hypothesis of Schizophrenia",
      "passage_type": "paragraph",
      "passage": "The dopamine hypothesis proposes that schizophrenia symptoms result from dysregulated dopamine activity in the brain:",
      "id": "PETH-0370"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "High-Potency Typical Antipsychotics",
      "passage_type": "paragraph",
      "passage": "Require lower doses; greater risk of EPS; lower risk of sedation and anticholinergic effects.",
      "id": "PETH-0371"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "antipsychotics.html",
      "chapter_title": "Antipsychotics",
      "section": "Low-Potency Typical Antipsychotics",
      "passage_type": "paragraph",
      "passage": "Require higher doses; lower risk of EPS; greater sedation, anticholinergic effects, and orthostatic hypotension.",
      "id": "PETH-0372"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Clinical Considerations",
      "passage_type": "paragraph",
      "passage": "Rapid onset of action (minutes to hours), unlike antidepressants which take weeks",
      "id": "PETH-0373"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Clinical Considerations",
      "passage_type": "paragraph",
      "passage": "Tolerance and dependence develop with chronic use; benzodiazepines should generally be prescribed for short-term use",
      "id": "PETH-0374"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Clinical Considerations",
      "passage_type": "paragraph",
      "passage": "Withdrawal can be medically dangerous (seizures, delirium); must be tapered gradually, never stopped abruptly",
      "id": "PETH-0375"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Clinical Considerations",
      "passage_type": "paragraph",
      "passage": "Cross-tolerance exists with alcohol and barbiturates (all act on GABA receptors)",
      "id": "PETH-0376"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Clinical Considerations",
      "passage_type": "paragraph",
      "passage": "Benzodiazepines are respiratory depressants; combined with opioids or alcohol, the risk of fatal respiratory depression increases significantly",
      "id": "PETH-0377"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Clinical Considerations",
      "passage_type": "paragraph",
      "passage": "Older adults are at increased risk for falls, cognitive impairment, and paradoxical reactions (agitation, disinhibition)",
      "id": "PETH-0378"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Buspirone (BuSpar)",
      "passage_type": "paragraph",
      "passage": "Mechanism: Partial agonist at serotonin 5-HT1A receptors; does not act on GABA receptors",
      "id": "PETH-0379"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Buspirone (BuSpar)",
      "passage_type": "paragraph",
      "passage": "Onset: Takes 2-4 weeks to reach full effect (similar to antidepressants), making it unsuitable for acute anxiety relief",
      "id": "PETH-0380"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Buspirone (BuSpar)",
      "passage_type": "paragraph",
      "passage": "Advantages: No sedation, no tolerance or dependence, no withdrawal syndrome, no cross-tolerance with alcohol/benzodiazepines, no abuse potential",
      "id": "PETH-0381"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Buspirone (BuSpar)",
      "passage_type": "paragraph",
      "passage": "Disadvantages: Slow onset; not effective for acute anxiety or panic; patients who have previously used benzodiazepines may perceive it as ineffective due to the absence of the immediate sedating effect",
      "id": "PETH-0382"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Memantine (Namenda)",
      "passage_type": "paragraph",
      "passage": "Mechanism: NMDA receptor antagonist; blocks excessive glutamate activity (thought to protect against excitotoxicity)",
      "id": "PETH-0383"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Memantine (Namenda)",
      "passage_type": "paragraph",
      "passage": "Uses: Moderate to severe Alzheimer's disease; often used in combination with a cholinesterase inhibitor",
      "id": "PETH-0384"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Memantine (Namenda)",
      "passage_type": "paragraph",
      "passage": "Side effects: Generally well-tolerated; dizziness, headache, constipation, confusion",
      "id": "PETH-0385"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Benzodiazepines enhance GABA activity; rapid onset but carry risks of dependence, tolerance, and dangerous withdrawal (seizures). Never discontinue abruptly.",
      "id": "PETH-0386"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Buspirone is a 5-HT1A partial agonist; no sedation, no dependence, no cross-tolerance with alcohol; takes 2-4 weeks to work.",
      "id": "PETH-0387"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) increase acetylcholine and are used for mild to moderate Alzheimer's.",
      "id": "PETH-0388"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Anti-dementia drugs slow symptom progression but do not cure or reverse the disease.",
      "id": "PETH-0389"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "anxiolytics-sedatives.html",
      "chapter_title": "Anxiolytics & Sedatives",
      "section": "Buspirone (BuSpar)",
      "passage_type": "paragraph",
      "passage": "Buspirone is a non-benzodiazepine anxiolytic used primarily for generalized anxiety disorder (GAD).",
      "id": "PETH-0390"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.03: Informed Consent in Assessments",
      "passage_type": "paragraph",
      "passage": "Informed consent is implied because testing is conducted as a routine educational, institutional, or organizational activity (e.g., admission testing)",
      "id": "PETH-0391"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Balancing Security and Client Rights",
      "passage_type": "paragraph",
      "passage": "A client should not receive the test manual, scoring key, or stimulus materials (test materials)",
      "id": "PETH-0392"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Balancing Security and Client Rights",
      "passage_type": "paragraph",
      "passage": "When test data are intertwined with test materials (e.g., a response booklet that includes test questions), the psychologist must use professional judgment to balance client rights with test security",
      "id": "PETH-0393"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Psychologists base assessment opinions on sufficient information and appropriate techniques (9.01). When personal examination is not possible, they must document limitations and qualify their conclusions.",
      "id": "PETH-0394"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Assessment instruments must be valid and reliable for the specific population and purpose (9.02). Cultural, linguistic, and individual factors must be considered.",
      "id": "PETH-0395"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Informed consent is required for assessments except when mandated by law, implied by context, or evaluating decisional capacity (9.03).",
      "id": "PETH-0396"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Test data (scores, responses, observations) can be released to clients upon request; test materials (manuals, questions, stimuli) are protected for test security (9.04 vs. 9.11).",
      "id": "PETH-0397"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Psychologists do not use obsolete tests or outdated test results for current purposes (9.08).",
      "id": "PETH-0398"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Computer-based interpretations are tools, not substitutes for clinical judgment; the psychologist retains responsibility for the final interpretation (9.09).",
      "id": "PETH-0399"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Assessment results should be explained to the individual unless the person was informed in advance that results would not be shared (9.10).",
      "id": "PETH-0400"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Psychologists retain full responsibility for assessment even when administration or scoring is delegated to others (9.07).",
      "id": "PETH-0401"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "Standard 9.03: Informed Consent in Assessments",
      "passage_type": "paragraph",
      "passage": "Psychologists obtain informed consent for assessments, evaluations, or diagnostic services, except when:",
      "id": "PETH-0402"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "assessment-ethics.html",
      "chapter_title": "Assessment (Std 9)",
      "section": "9.04(b) -- Absent Client Release",
      "passage_type": "paragraph",
      "passage": "In the absence of a client release, psychologists provide test data only as required by law or court order.",
      "id": "PETH-0403"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Standard 2.03: Maintaining Competence",
      "passage_type": "paragraph",
      "passage": "Staying current with scientific and professional developments in their areas of practice",
      "id": "PETH-0404"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Standard 2.04: Bases for Scientific and Professional Judgments",
      "passage_type": "paragraph",
      "passage": "Clinical judgment informed by training and experience, not personal bias or speculation",
      "id": "PETH-0405"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Standard 2.05: Delegation of Work to Others",
      "passage_type": "paragraph",
      "passage": "Take reasonable steps to avoid delegating work to persons with a multiple relationship with those being served",
      "id": "PETH-0406"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Standard 2.05: Delegation of Work to Others",
      "passage_type": "paragraph",
      "passage": "Authorize only those responsibilities the person can be expected to perform competently based on their education, training, or experience",
      "id": "PETH-0407"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "2.06(b) -- Taking Appropriate Action",
      "passage_type": "paragraph",
      "passage": "Determining whether they should limit, suspend, or terminate work-related duties",
      "id": "PETH-0408"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Psychologists practice only within the boundaries of their competence based on education, training, supervised experience, consultation, study, or professional experience.",
      "id": "PETH-0409"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "The emergency exception (2.02) allows temporary practice outside competence boundaries when no other provider is available during a crisis.",
      "id": "PETH-0410"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Maintaining competence (2.03) is an ongoing obligation requiring continuing education and professional development.",
      "id": "PETH-0411"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Professional judgments must be based on established scientific and professional knowledge (2.04), not personal opinion or speculation.",
      "id": "PETH-0412"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "When delegating work (2.05), the psychologist retains responsibility for ensuring the quality and competence of the delegated services.",
      "id": "PETH-0413"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Personal problems that may impair functioning must be addressed proactively (2.06) through consultation, therapy, or limiting practice.",
      "id": "PETH-0414"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Scope of practice (legal) differs from competence (ethical); a psychologist may have legal authority to perform an activity without having individual competence to do so.",
      "id": "PETH-0415"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Standard 2.03: Maintaining Competence",
      "passage_type": "paragraph",
      "passage": "Psychologists undertake ongoing efforts to develop and maintain their competence. This includes:",
      "id": "PETH-0416"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Standard 2.05: Delegation of Work to Others",
      "passage_type": "paragraph",
      "passage": "Psychologists who delegate work to employees, supervisees, research or teaching assistants, or others:",
      "id": "PETH-0417"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "competence.html",
      "chapter_title": "Competence (Std 2)",
      "section": "Competence vs. Scope of Practice",
      "passage_type": "paragraph",
      "passage": "These are related but distinct concepts:",
      "id": "PETH-0418"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Faculty may not serve as therapists for students they evaluate (Standard 7.05); students in mandatory therapy programs must choose from unaffiliated practitioners.",
      "id": "PETH-0419"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Sexual relationships with students/supervisees are always prohibited (Standard 7.07).",
      "id": "PETH-0420"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Students cannot be required to disclose personal information (sexual history, abuse history, etc.) unless the program clearly identified this requirement in admissions materials or the information is needed to address competence/safety concerns.",
      "id": "PETH-0421"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Education and training programs must accurately describe their content, goals, requirements, and benefits.",
      "id": "PETH-0422"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "education-training.html",
      "chapter_title": "Education & Training (Std 7)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Student evaluations must be based on actual performance and established program requirements (Standard 7.06).",
      "id": "PETH-0423"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Structure of the Ethics Code",
      "passage_type": "paragraph",
      "passage": "Preamble -- States the purpose and scope of the Ethics Code. It establishes that psychologists commit to increasing knowledge, improving conditions, and helping the public develop informed judgments about behavior.",
      "id": "PETH-0424"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Structure of the Ethics Code",
      "passage_type": "paragraph",
      "passage": "General Principles (A through E) -- Aspirational goals that guide psychologists toward the highest ideals. They are not enforceable but provide a framework for ethical reasoning.",
      "id": "PETH-0425"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Structure of the Ethics Code",
      "passage_type": "paragraph",
      "passage": "Ethical Standards (1 through 10) -- Enforceable rules that set mandatory obligations. Violations can result in sanctions, license revocation, or expulsion from APA.",
      "id": "PETH-0426"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Structure of the Ethics Code",
      "passage_type": "paragraph",
      "passage": "Introduction and Applicability -- Clarifies how the Code applies, its relationship to law, and issues of jurisdiction.",
      "id": "PETH-0427"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Applicability and Enforcement",
      "passage_type": "paragraph",
      "passage": "The Ethics Code applies to APA members and to psychologists licensed under state laws that adopt the Code, covering professional, scientific, and educational activities.",
      "id": "PETH-0428"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Applicability and Enforcement",
      "passage_type": "paragraph",
      "passage": "The Code does not apply to psychologists' purely private conduct that is not connected to their professional roles.",
      "id": "PETH-0429"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Applicability and Enforcement",
      "passage_type": "paragraph",
      "passage": "Lack of awareness or misunderstanding of an Ethical Standard is not a defense to a charge of unethical conduct.",
      "id": "PETH-0430"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Applicability and Enforcement",
      "passage_type": "paragraph",
      "passage": "The Ethics Code is not intended to be a basis of civil liability; whether a psychologist has violated the Ethics Code does not itself determine legal liability.",
      "id": "PETH-0431"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Applicability and Enforcement",
      "passage_type": "paragraph",
      "passage": "The modifiers \"reasonably,\" \"appropriate,\" and \"potentially\" in the Standards allow for professional judgment but require that the psychologist's actions be justifiable given the circumstances.",
      "id": "PETH-0432"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Applicability and Enforcement",
      "passage_type": "paragraph",
      "passage": "When the Ethics Code establishes a higher standard than the law, psychologists must meet the ethical standard. When the law establishes a higher standard, psychologists must comply with the law.",
      "id": "PETH-0433"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "General Principles (A-E) are aspirational and not enforceable; Ethical Standards (1-10) are enforceable.",
      "id": "PETH-0434"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Principle A = Beneficence/Nonmaleficence; B = Fidelity/Responsibility; C = Integrity; D = Justice; E = Respect for Rights and Dignity.",
      "id": "PETH-0435"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "When ethics conflict with law, clarify the conflict, advocate for the Ethics Code, and resolve consistent with the Code (Standard 1.02).",
      "id": "PETH-0436"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "First response to learning of a colleague's ethical violation is usually informal resolution (Standard 1.04), unless it would violate confidentiality or the violation is severe.",
      "id": "PETH-0437"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Consultation and documentation are essential components of ethical decision-making.",
      "id": "PETH-0438"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Virtue ethics complements rule-based codes by focusing on professional character.",
      "id": "PETH-0439"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Structure of the Ethics Code",
      "passage_type": "paragraph",
      "passage": "The APA Ethics Code consists of four major components:",
      "id": "PETH-0440"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "ethics-overview.html",
      "chapter_title": "Ethics Code Overview & General Principles",
      "section": "Applicability and Enforcement",
      "passage_type": "paragraph",
      "passage": "Several important points about the scope and enforcement of the Ethics Code frequently appear on the EPPP:",
      "id": "PETH-0441"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.02: Sexual Harassment",
      "passage_type": "paragraph",
      "passage": "Is unwelcome, offensive, or creates a hostile workplace or educational environment, and the psychologist knows or is told this, or",
      "id": "PETH-0442"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.02: Sexual Harassment",
      "passage_type": "paragraph",
      "passage": "Is sufficiently severe or intense to be abusive to a reasonable person in the context",
      "id": "PETH-0443"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.05: Multiple Relationships",
      "passage_type": "clinical_note",
      "passage": "Is in a relationship with a person closely associated with or related to the person with whom the psychologist has the professional relationship, or",
      "id": "PETH-0444"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.05: Multiple Relationships",
      "passage_type": "clinical_note",
      "passage": "Promises to enter into another relationship in the future with the person or a person closely associated with the person",
      "id": "PETH-0445"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "When Multiple Relationships Are Prohibited",
      "passage_type": "clinical_note",
      "passage": "Risk exploitation of or harm to the person with whom the professional relationship exists",
      "id": "PETH-0446"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Managing Unavoidable Multiple Relationships",
      "passage_type": "clinical_note",
      "passage": "Referring the client to another provider if the relationship cannot be managed ethically",
      "id": "PETH-0447"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.06: Conflict of Interest",
      "passage_type": "paragraph",
      "passage": "Expose the person or organization with whom the professional relationship exists to harm or exploitation",
      "id": "PETH-0448"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Multiple relationships are not automatically unethical -- they are problematic only when they could reasonably impair objectivity or risk exploitation/harm.",
      "id": "PETH-0449"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Boundary crossings (e.g., accepting a small gift, attending a public event) differ from boundary violations (e.g., sexual relationships, business partnerships with clients).",
      "id": "PETH-0450"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "In rural or small communities, multiple relationships may be unavoidable; the ethical response is to manage them carefully with documentation and consultation.",
      "id": "PETH-0451"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Sexual intimacies with current clients, their relatives, or current students/supervisees are always prohibited.",
      "id": "PETH-0452"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "The two-year rule applies to sexual intimacies with former therapy clients (Standard 10.08), with the burden on the psychologist to demonstrate no exploitation even after two years.",
      "id": "PETH-0453"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Psychologists may never accept as therapy clients persons with whom they have had sexual relationships (Standard 10.07).",
      "id": "PETH-0454"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Third-party referrals require clarification of roles, relationships, and confidentiality limits at the outset (Standard 3.07).",
      "id": "PETH-0455"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Informed consent must be obtained as early as possible and include information about the nature of therapy, fees, confidentiality limits, and the right to withdraw.",
      "id": "PETH-0456"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "When Multiple Relationships Are Prohibited",
      "passage_type": "paragraph",
      "passage": "A psychologist refrains from entering into a multiple relationship if the relationship could reasonably be expected to:",
      "id": "PETH-0457"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.07: Third-Party Requests for Services",
      "passage_type": "paragraph",
      "passage": "When psychologists agree to provide services at the request of a third party, they clarify at the outset:",
      "id": "PETH-0458"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Standard 3.07: Third-Party Requests for Services",
      "passage_type": "paragraph",
      "passage": "This standard commonly applies in forensic, organizational, custody evaluation, and insurance-related contexts.",
      "id": "PETH-0459"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Sexual Relationships: Standards 3.05 and 10.05-10.08",
      "passage_type": "paragraph",
      "passage": "Sexual intimacies with clients and other protected parties receive special attention in the Ethics Code:",
      "id": "PETH-0460"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "human-relations.html",
      "chapter_title": "Human Relations (Std 3)",
      "section": "Informed Consent in Therapy (Standard 10.01)",
      "passage_type": "paragraph",
      "passage": "Psychologists inform clients as early as possible in the therapeutic relationship about:",
      "id": "PETH-0461"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Lithium (Eskalith, Lithobid)",
      "passage_type": "paragraph",
      "passage": "Mechanism: Not fully understood; may affect second messenger systems (inositol phosphate pathway), modulate neurotransmitter release, and influence gene expression",
      "id": "PETH-0462"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Lithium (Eskalith, Lithobid)",
      "passage_type": "paragraph",
      "passage": "Therapeutic level: 0.6-1.2 mEq/L (narrow therapeutic index -- levels must be monitored regularly)",
      "id": "PETH-0463"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Lithium (Eskalith, Lithobid)",
      "passage_type": "paragraph",
      "passage": "Toxicity: Levels above 1.5 mEq/L can be dangerous; above 2.0 mEq/L is a medical emergency",
      "id": "PETH-0464"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Signs of Lithium Toxicity",
      "passage_type": "paragraph",
      "passage": "Moderate (2.0-2.5): Confusion, ataxia, coarse tremor, fasciculations, dysarthria",
      "id": "PETH-0465"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Side Effects and Monitoring",
      "passage_type": "paragraph",
      "passage": "Renal: Nephrogenic diabetes insipidus (polyuria, polydipsia); long-term kidney damage possible",
      "id": "PETH-0466"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Side Effects and Monitoring",
      "passage_type": "paragraph",
      "passage": "Teratogenicity: Ebstein's anomaly (cardiac malformation in the fetus); contraindicated in first trimester of pregnancy",
      "id": "PETH-0467"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Side Effects and Monitoring",
      "passage_type": "paragraph",
      "passage": "Dehydration, NSAIDs, and low-sodium diets can increase lithium levels to toxic ranges",
      "id": "PETH-0468"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Valproate / Valproic Acid (Depakote, Depakene)",
      "passage_type": "paragraph",
      "passage": "Uses: Bipolar disorder (especially mixed episodes and rapid cycling), seizure disorders, migraine prophylaxis",
      "id": "PETH-0469"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Valproate / Valproic Acid (Depakote, Depakene)",
      "passage_type": "paragraph",
      "passage": "Side effects: GI disturbances, weight gain, tremor, hair loss (alopecia), sedation",
      "id": "PETH-0470"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Valproate / Valproic Acid (Depakote, Depakene)",
      "passage_type": "paragraph",
      "passage": "Serious risks: Hepatotoxicity (liver failure, especially in children under 2); pancreatitis; neural tube defects in pregnancy (spina bifida -- Category X, contraindicated in pregnancy)",
      "id": "PETH-0471"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Carbamazepine (Tegretol)",
      "passage_type": "paragraph",
      "passage": "Serious risks: Aplastic anemia and agranulocytosis (requires CBC monitoring); Stevens-Johnson syndrome (severe skin reaction); hepatotoxicity; neural tube defects in pregnancy",
      "id": "PETH-0472"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Carbamazepine (Tegretol)",
      "passage_type": "paragraph",
      "passage": "Drug interactions: Potent inducer of CYP3A4 enzymes; reduces effectiveness of oral contraceptives and many other medications; also induces its own metabolism (autoinduction)",
      "id": "PETH-0473"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Lamotrigine (Lamictal)",
      "passage_type": "paragraph",
      "passage": "Uses: Bipolar disorder maintenance (especially effective for preventing bipolar depression); seizure disorders",
      "id": "PETH-0474"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Lamotrigine (Lamictal)",
      "passage_type": "paragraph",
      "passage": "Advantages: Does not cause weight gain; may improve cognition; effective for bipolar depression",
      "id": "PETH-0475"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Lamotrigine (Lamictal)",
      "passage_type": "paragraph",
      "passage": "Serious risk: Stevens-Johnson syndrome (potentially fatal skin reaction); risk is minimized by very slow dose titration; risk increases with rapid titration or concurrent valproate use",
      "id": "PETH-0476"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Lithium has a narrow therapeutic index (0.6-1.2 mEq/L); requires monitoring of renal and thyroid function; causes Ebstein's anomaly in pregnancy.",
      "id": "PETH-0477"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Valproate causes neural tube defects (Category X in pregnancy) and hepatotoxicity.",
      "id": "PETH-0478"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Carbamazepine causes aplastic anemia, Stevens-Johnson syndrome, and induces CYP enzymes (many drug interactions, including autoinduction).",
      "id": "PETH-0479"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Lamotrigine must be titrated slowly to prevent Stevens-Johnson syndrome; most effective mood stabilizer for bipolar depression prevention.",
      "id": "PETH-0480"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "mood-stabilizers.html",
      "chapter_title": "Mood Stabilizers",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Lithium is the only mood stabilizer with strong evidence for reducing suicidality.",
      "id": "PETH-0481"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Absorption",
      "passage_type": "paragraph",
      "passage": "Oral bioavailability -- the fraction of an orally administered drug that reaches systemic circulation in unchanged form. This is always less than 100% for oral drugs due to incomplete absorption and first-pass metabolism.",
      "id": "PETH-0482"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Absorption",
      "passage_type": "paragraph",
      "passage": "First-pass metabolism -- after oral absorption, drugs pass through the liver via the portal vein before reaching systemic circulation. The liver may metabolize a significant portion of the drug on this \"first pass,\" substantially reducing the amount of active drug that reaches the brain. Example: some drugs (e.g., buspirone) have very low oral bioavailability due to extensive first-pass metabolism.",
      "id": "PETH-0483"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Absorption",
      "passage_type": "paragraph",
      "passage": "Factors affecting absorption include: drug formulation, gastric pH, food in the stomach, GI motility, and drug-drug interactions at the gut level.",
      "id": "PETH-0484"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Distribution",
      "passage_type": "paragraph",
      "passage": "Protein binding -- many drugs bind to plasma proteins (primarily albumin). Only the unbound (free) fraction is pharmacologically active, able to cross membranes, and available for metabolism. Drugs with high protein binding (e.g., >95%) may be displaced by other protein-bound drugs, leading to transient increases in the free fraction and potentially toxic effects.",
      "id": "PETH-0485"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Distribution",
      "passage_type": "paragraph",
      "passage": "Blood-brain barrier (BBB) -- a selective, semi-permeable barrier formed by tight junctions between brain capillary endothelial cells. Psychotropic medications must cross the BBB to exert their CNS effects. Lipophilic (fat-soluble), small, and uncharged molecules cross more readily. The BBB is the primary reason that many peripherally active drugs do not cause CNS side effects.",
      "id": "PETH-0486"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Distribution",
      "passage_type": "paragraph",
      "passage": "Volume of distribution (Vd) -- a theoretical measure of the total body space available to a drug. A large Vd indicates the drug distributes extensively into tissues (e.g., is highly lipophilic); a small Vd indicates it stays mostly in the plasma. Highly lipophilic psychotropics (e.g., diazepam) have large volumes of distribution and may accumulate in adipose tissue.",
      "id": "PETH-0487"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Metabolism (Biotransformation)",
      "passage_type": "paragraph",
      "passage": "Phase I reactions -- oxidation, reduction, and hydrolysis reactions that introduce or expose a functional group on the drug molecule. The most important Phase I enzymes are the cytochrome P450 (CYP450) family. Phase I reactions may produce active metabolites (e.g., fluoxetine is metabolized to the active metabolite norfluoxetine).",
      "id": "PETH-0488"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Metabolism (Biotransformation)",
      "passage_type": "paragraph",
      "passage": "Phase II reactions -- conjugation reactions (glucuronidation, sulfation, acetylation) that attach a large polar group to the drug or its Phase I metabolite, making it highly water-soluble and readily excreted. Phase II metabolites are almost always pharmacologically inactive.",
      "id": "PETH-0489"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Excretion (Elimination)",
      "passage_type": "paragraph",
      "passage": "Renal excretion -- the kidneys filter water-soluble metabolites into the urine. This is the primary route for most drug metabolites. Impaired renal function can lead to drug accumulation and toxicity. Lithium, which is not metabolized but excreted entirely by the kidneys, is a critical example -- renal impairment, dehydration, or sodium depletion can cause dangerous lithium accumulation.",
      "id": "PETH-0490"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Excretion (Elimination)",
      "passage_type": "paragraph",
      "passage": "Hepatic (biliary) excretion -- some drugs are excreted into bile and eliminated in the feces. Some undergo enterohepatic recirculation, where the drug is reabsorbed from the intestines, effectively prolonging its duration of action.",
      "id": "PETH-0491"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Principles",
      "passage_type": "paragraph",
      "passage": "Steady state is reached after approximately 5 half-lives of continuous dosing. At steady state, the amount of drug being administered equals the amount being eliminated, and plasma levels plateau.",
      "id": "PETH-0492"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Principles",
      "passage_type": "paragraph",
      "passage": "Similarly, after discontinuation, it takes approximately 5 half-lives for a drug to be essentially eliminated from the body (~97% eliminated).",
      "id": "PETH-0493"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Principles",
      "passage_type": "paragraph",
      "passage": "Half-life determines dosing frequency: drugs with short half-lives (e.g., venlafaxine, ~5 hours) often need twice-daily or extended-release dosing, while drugs with long half-lives (e.g., fluoxetine, ~2-6 days) may be given once daily.",
      "id": "PETH-0494"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Principles",
      "passage_type": "paragraph",
      "passage": "Washout period -- the time needed for a drug to be cleared from the body before starting a new medication (to avoid interactions). This is directly related to half-life. Example: the 5-week washout required when switching from fluoxetine to an MAOI reflects fluoxetine's extremely long half-life (plus its active metabolite norfluoxetine).",
      "id": "PETH-0495"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacogenomics: Poor vs. Extensive Metabolizers",
      "passage_type": "paragraph",
      "passage": "Poor metabolizers (PMs) -- have reduced or absent enzyme activity. Drugs metabolized by that enzyme accumulate to higher levels, increasing the risk of side effects and toxicity at standard doses. Example: CYP2D6 poor metabolizers may experience toxic effects from standard doses of codeine (though paradoxically, they may get less analgesic effect from codeine, since codeine requires CYP2D6 conversion to morphine).",
      "id": "PETH-0496"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacogenomics: Poor vs. Extensive Metabolizers",
      "passage_type": "paragraph",
      "passage": "Extensive metabolizers (EMs) -- have normal enzyme activity and respond predictably to standard doses.",
      "id": "PETH-0497"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacogenomics: Poor vs. Extensive Metabolizers",
      "passage_type": "paragraph",
      "passage": "Ultrarapid metabolizers (UMs) -- have excess enzyme activity due to gene duplication. They metabolize drugs too quickly, resulting in subtherapeutic levels at standard doses. Ultrarapid CYP2D6 metabolizers may convert codeine to morphine too rapidly, leading to opioid toxicity.",
      "id": "PETH-0498"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Drug-Receptor Interactions",
      "passage_type": "paragraph",
      "passage": "Agonist -- a drug that binds to a receptor and activates it, producing a biological response. It mimics the effect of the endogenous neurotransmitter. Example: benzodiazepines are agonists at the GABA-A receptor (they enhance GABA's effect at the receptor).",
      "id": "PETH-0499"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Drug-Receptor Interactions",
      "passage_type": "paragraph",
      "passage": "Antagonist -- a drug that binds to a receptor and blocks it, preventing activation by the endogenous neurotransmitter. It has affinity for the receptor but no intrinsic activity (efficacy). Example: haloperidol is a dopamine D2 receptor antagonist.",
      "id": "PETH-0500"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Drug-Receptor Interactions",
      "passage_type": "paragraph",
      "passage": "Partial agonist -- a drug that binds to and activates a receptor but produces only a submaximal response, even at full receptor occupancy. Partial agonists can act as functional agonists in low-neurotransmitter states and as functional antagonists in high-neurotransmitter states, providing a \"stabilizing\" effect. Example: aripiprazole is a partial agonist at the D2 receptor; buspirone is a partial agonist at 5-HT1A.",
      "id": "PETH-0501"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Drug-Receptor Interactions",
      "passage_type": "paragraph",
      "passage": "Inverse agonist -- a drug that binds to a receptor and produces an effect opposite to that of an agonist. This is distinct from an antagonist, which simply blocks receptor activation. Some researchers consider certain beta-carbolines to be inverse agonists at the benzodiazepine site on GABA-A receptors (they reduce GABA activity below baseline).",
      "id": "PETH-0502"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Affinity and Efficacy",
      "passage_type": "paragraph",
      "passage": "Affinity -- how strongly a drug binds to its receptor. High affinity means the drug binds tightly and at low concentrations. Both agonists and antagonists have affinity.",
      "id": "PETH-0503"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Affinity and Efficacy",
      "passage_type": "paragraph",
      "passage": "Efficacy (intrinsic activity) -- the ability of a drug to activate the receptor once bound. Full agonists have high efficacy; partial agonists have intermediate efficacy; antagonists have zero efficacy.",
      "id": "PETH-0504"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Dose-Response Relationships",
      "passage_type": "paragraph",
      "passage": "ED50 -- the dose that produces a therapeutic effect in 50% of the population (or 50% of the maximal effect in a single individual).",
      "id": "PETH-0505"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Dose-Response Relationships",
      "passage_type": "paragraph",
      "passage": "LD50 -- the dose that is lethal to 50% of the population (determined in animal studies).",
      "id": "PETH-0506"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Dose-Response Relationships",
      "passage_type": "paragraph",
      "passage": "Therapeutic index (TI) -- the ratio of LD50 to ED50 (TI = LD50 / ED50). A higher therapeutic index means a wider margin of safety.",
      "id": "PETH-0507"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Wide Therapeutic Index Drugs",
      "passage_type": "paragraph",
      "passage": "SSRIs -- wide therapeutic index; difficult to cause lethal overdose with SSRIs alone. This is a major advantage over TCAs and MAOIs, particularly in patients with suicidal ideation.",
      "id": "PETH-0508"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Wide Therapeutic Index Drugs",
      "passage_type": "paragraph",
      "passage": "Most benzodiazepines (when taken alone) -- wide TI, but significantly narrowed when combined with other CNS depressants (alcohol, opioids).",
      "id": "PETH-0509"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacokinetic Interactions",
      "passage_type": "paragraph",
      "passage": "CYP450 inhibition -- one drug inhibits the metabolism of another, causing the second drug to accumulate (increased levels, greater risk of toxicity). Example: fluvoxamine (CYP1A2 inhibitor) dramatically increases clozapine levels (CYP1A2 substrate), potentially causing toxicity.",
      "id": "PETH-0510"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacokinetic Interactions",
      "passage_type": "paragraph",
      "passage": "CYP450 induction -- one drug induces (increases the expression of) CYP450 enzymes, causing a second drug to be metabolized faster (decreased levels, reduced efficacy). Example: carbamazepine (CYP3A4 inducer) reduces the effectiveness of oral contraceptives (CYP3A4 substrate).",
      "id": "PETH-0511"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacokinetic Interactions",
      "passage_type": "paragraph",
      "passage": "Protein binding displacement -- one highly protein-bound drug displaces another from plasma proteins, transiently increasing the free fraction of the displaced drug.",
      "id": "PETH-0512"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacokinetic Interactions",
      "passage_type": "paragraph",
      "passage": "Altered renal excretion -- drugs that affect renal function or urinary pH can alter the excretion rate of other drugs. Example: thiazide diuretics reduce lithium clearance, increasing lithium levels and toxicity risk.",
      "id": "PETH-0513"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacodynamic Interactions",
      "passage_type": "paragraph",
      "passage": "Additive effects -- the combined effect equals the sum of each drug's individual effect (1 + 1 = 2). Example: combining two CNS depressants (e.g., a benzodiazepine and alcohol) produces additive sedation.",
      "id": "PETH-0514"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacodynamic Interactions",
      "passage_type": "paragraph",
      "passage": "Synergistic effects -- the combined effect is greater than the sum of individual effects (1 + 1 = 3). Example: combining an SSRI with an MAOI can produce synergistic serotonergic effects, potentially causing life-threatening serotonin syndrome.",
      "id": "PETH-0515"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacodynamic Interactions",
      "passage_type": "paragraph",
      "passage": "Antagonistic effects -- one drug reduces or blocks the effect of another (1 + 1 = 0.5). Example: a dopamine agonist used for Parkinson's disease may counteract the dopamine-blocking effects of an antipsychotic.",
      "id": "PETH-0516"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Mood regulation -- serotonin deficiency is implicated in depression (the \"serotonin hypothesis,\" though this is an oversimplification)",
      "id": "PETH-0517"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Sleep-wake cycle -- involved in both sleep onset (via 5-HT2A) and wakefulness; precursor to melatonin",
      "id": "PETH-0518"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Appetite and satiety -- serotonergic activity in the hypothalamus promotes satiety; this is why SSRIs may initially cause appetite reduction",
      "id": "PETH-0519"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Pain modulation -- descending serotonergic pathways inhibit pain transmission (basis for SNRIs and TCAs in chronic pain treatment)",
      "id": "PETH-0520"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Anxiety -- implicated in both the pathophysiology and treatment of OCD, panic disorder, social anxiety, and PTSD",
      "id": "PETH-0521"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Gastrointestinal function -- ~90% of the body's serotonin is found in the gut; this explains the GI side effects of SSRIs",
      "id": "PETH-0522"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Alertness and arousal -- the locus coeruleus is the brain's \"alarm system\"; norepinephrine increases vigilance and attention",
      "id": "PETH-0523"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Attention and concentration -- NE enhances the signal-to-noise ratio in cortical processing; deficits are implicated in ADHD",
      "id": "PETH-0524"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Fight-or-flight response -- NE activates the sympathetic nervous system; excess NE activity is implicated in anxiety, panic disorder, and PTSD hyperarousal",
      "id": "PETH-0525"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Mood -- NE deficiency is implicated in depression, particularly symptoms of fatigue, low energy, and poor concentration (the basis for SNRIs and TCAs)",
      "id": "PETH-0526"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Pain modulation -- descending noradrenergic pathways contribute to pain inhibition (basis for duloxetine in neuropathic pain)",
      "id": "PETH-0527"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Memory and learning -- acetylcholine is essential for memory encoding and attention; cholinergic deficits are central to the cognitive impairment in Alzheimer's disease",
      "id": "PETH-0528"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Attention and arousal -- cortical ACh modulates attention and sensory processing",
      "id": "PETH-0529"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Functions",
      "passage_type": "paragraph",
      "passage": "Peripheral functions -- neuromuscular junction transmission (skeletal muscle contraction); parasympathetic nervous system activity (\"rest and digest\")",
      "id": "PETH-0530"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Anticholinergic Effects",
      "passage_type": "paragraph",
      "passage": "Cognitive impairment (confusion, memory problems -- especially concerning in elderly patients)",
      "id": "PETH-0531"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Cholinesterase Inhibitors",
      "passage_type": "paragraph",
      "passage": "Donepezil (Aricept) -- most widely prescribed; once-daily dosing; approved for all stages of Alzheimer's",
      "id": "PETH-0532"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Cholinesterase Inhibitors",
      "passage_type": "paragraph",
      "passage": "Rivastigmine (Exelon) -- available as a transdermal patch; inhibits both acetylcholinesterase and butyrylcholinesterase",
      "id": "PETH-0533"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pediatric Considerations",
      "passage_type": "paragraph",
      "passage": "Immature hepatic and renal function: Neonates and young infants have reduced hepatic enzyme activity and immature renal function, leading to slower drug metabolism and excretion. However, children aged 2-12 often have faster hepatic metabolism per kilogram of body weight than adults (higher CYP activity relative to body size), sometimes requiring higher weight-adjusted doses.",
      "id": "PETH-0534"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pediatric Considerations",
      "passage_type": "paragraph",
      "passage": "FDA Black Box Warning on SSRIs: The FDA issued a black box warning (the most serious drug warning) on all antidepressants regarding increased risk of suicidal thinking and behavior in children, adolescents, and young adults under age 25. This warning was based on meta-analyses of clinical trials showing approximately double the risk of suicidal ideation (4% vs. 2%) in youth taking antidepressants vs. placebo. Importantly, no completed suicides occurred in these trials, and the warning does not apply to adults over 25.",
      "id": "PETH-0535"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pediatric Considerations",
      "passage_type": "paragraph",
      "passage": "Off-label prescribing: Many psychotropic medications used in pediatric populations are prescribed off-label (not FDA-approved for that age group or indication), because clinical trials in children are limited. Fluoxetine is one of the few SSRIs with FDA approval for pediatric depression (ages 8+). Stimulants (methylphenidate, amphetamine salts) are well-studied and FDA-approved for pediatric ADHD.",
      "id": "PETH-0536"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pediatric Considerations",
      "passage_type": "paragraph",
      "passage": "Developmental pharmacodynamics: Children's neurotransmitter systems are still developing, which may alter both the therapeutic and adverse effects of psychotropic medications. The developing brain may be more sensitive to certain effects (e.g., metabolic effects of atypical antipsychotics, growth suppression from stimulants).",
      "id": "PETH-0537"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Geriatric Considerations",
      "passage_type": "paragraph",
      "passage": "Decreased hepatic clearance: Aging reduces liver blood flow, liver mass, and CYP450 enzyme activity, resulting in slower drug metabolism. Phase I metabolism (CYP450) is more affected by aging than Phase II (conjugation) reactions. This is clinically relevant because many psychotropics undergo Phase I metabolism.",
      "id": "PETH-0538"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Geriatric Considerations",
      "passage_type": "paragraph",
      "passage": "Decreased renal clearance: Glomerular filtration rate (GFR) declines with age. This is particularly important for drugs excreted primarily by the kidneys, such as lithium. Older adults require lower lithium doses and more frequent monitoring.",
      "id": "PETH-0539"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Geriatric Considerations",
      "passage_type": "paragraph",
      "passage": "Polypharmacy: Elderly patients often take multiple medications for concurrent conditions, dramatically increasing the risk of drug-drug interactions. Psychologists should be aware of the complete medication list when assessing cognitive and behavioral changes.",
      "id": "PETH-0540"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Geriatric Considerations",
      "passage_type": "paragraph",
      "passage": "Increased sensitivity to anticholinergic effects: Older adults are particularly vulnerable to anticholinergic cognitive effects (confusion, delirium, memory impairment), which can mimic or worsen dementia. Anticholinergic burden -- the cumulative anticholinergic effect of all medications a patient is taking -- is a significant concern.",
      "id": "PETH-0541"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Geriatric Considerations",
      "passage_type": "paragraph",
      "passage": "Beers Criteria: The American Geriatrics Society Beers Criteria is a widely used list of medications that are potentially inappropriate for older adults. Medications on the list include long-acting benzodiazepines (e.g., diazepam, chlordiazepoxide), strongly anticholinergic drugs (e.g., amitriptyline, diphenhydramine), and certain antipsychotics (black box warning for increased mortality in dementia-related psychosis).",
      "id": "PETH-0542"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pregnancy Categorization",
      "passage_type": "paragraph",
      "passage": "Former FDA categories (A/B/C/D/X): The FDA historically classified medications into five pregnancy categories: A (no risk in human studies), B (no risk in animal studies, no adequate human data), C (animal studies show risk, no adequate human data), D (evidence of human fetal risk, but benefits may outweigh risks), and X (contraindicated in pregnancy -- evidence of fetal abnormalities, risks clearly outweigh benefits).",
      "id": "PETH-0543"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pregnancy Categorization",
      "passage_type": "paragraph",
      "passage": "Current system (PLLR): In 2015, the FDA replaced the letter categories with the Pregnancy and Lactation Labeling Rule (PLLR), which requires a narrative format with specific subsections for pregnancy, lactation, and reproductive potential. This provides more nuanced, clinically useful information than the previous letter system. However, the old A-X categories remain widely referenced and tested.",
      "id": "PETH-0544"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Lactation Considerations",
      "passage_type": "paragraph",
      "passage": "Most psychotropic medications are excreted into breast milk to some degree. The amount transferred depends on the drug's molecular weight, lipophilicity, protein binding, and ionization.",
      "id": "PETH-0545"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Lactation Considerations",
      "passage_type": "paragraph",
      "passage": "Sertraline and paroxetine are generally considered among the SSRIs with the lowest transfer into breast milk (low relative infant dose).",
      "id": "PETH-0546"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Lactation Considerations",
      "passage_type": "paragraph",
      "passage": "Lithium is excreted in breast milk at significant levels (approximately 50% of maternal serum levels) and is generally avoided during breastfeeding due to the infant's immature renal function.",
      "id": "PETH-0547"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Lactation Considerations",
      "passage_type": "paragraph",
      "passage": "The decision to use psychotropic medications during breastfeeding involves weighing the benefits of breastfeeding and the risks of untreated maternal mental illness against the potential risks of infant drug exposure.",
      "id": "PETH-0548"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Renal and Hepatic Impairment",
      "passage_type": "paragraph",
      "passage": "Hepatic impairment: Reduced liver function decreases the capacity for Phase I (CYP450) and Phase II metabolism. Drugs that undergo extensive hepatic metabolism (most psychotropics) may accumulate, requiring dose reductions. Drugs that bypass hepatic metabolism (e.g., lithium, gabapentin, pregabalin -- all renally excreted) may be preferred when hepatic impairment is severe.",
      "id": "PETH-0549"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Renal and Hepatic Impairment",
      "passage_type": "paragraph",
      "passage": "Renal impairment: Reduced kidney function impairs the excretion of renally cleared drugs and their metabolites. Lithium is the most critical example -- it is excreted entirely by the kidneys, and even mild renal impairment can cause dangerous accumulation. Dose reduction and more frequent monitoring of serum levels are essential. Gabapentin and pregabalin also require renal dose adjustments.",
      "id": "PETH-0550"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Renal and Hepatic Impairment",
      "passage_type": "paragraph",
      "passage": "Dose adjustment approaches: For hepatic impairment, dose reduction is typically empirical (guided by clinical response and side effects, since no simple lab test directly predicts metabolic capacity in the way GFR predicts renal function). For renal impairment, dose adjustments are often guided by creatinine clearance or estimated GFR, with specific recommendations available for each drug.",
      "id": "PETH-0551"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "ADME (Absorption, Distribution, Metabolism, Excretion) determines a drug's plasma concentration over time. First-pass metabolism and protein binding are commonly tested concepts.",
      "id": "PETH-0552"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Half-life determines dosing frequency, time to steady state (~5 half-lives), and washout period. Know the half-lives of key drugs, especially fluoxetine (long) and venlafaxine (short).",
      "id": "PETH-0553"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "CYP450 enzymes (CYP2D6, CYP3A4, CYP1A2, CYP2C19) are responsible for most drug metabolism. Inhibitors raise substrate levels (toxicity risk); inducers lower them (treatment failure). Know key inhibitor-substrate pairs.",
      "id": "PETH-0554"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Pharmacogenomics: poor metabolizers accumulate drugs (toxicity risk); ultrarapid metabolizers clear drugs too fast (subtherapeutic levels).",
      "id": "PETH-0555"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Agonists activate receptors; antagonists block them; partial agonists provide a ceiling effect (e.g., aripiprazole, buspirone).",
      "id": "PETH-0556"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Therapeutic index (LD50/ED50): narrow TI drugs (lithium, carbamazepine) require blood level monitoring; wide TI drugs (SSRIs) are safer in overdose.",
      "id": "PETH-0557"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Serotonin (raphe nuclei) -- mood, sleep, appetite. Norepinephrine (locus coeruleus) -- alertness, attention. Dopamine (4 pathways) -- reward, motor control, cognition, prolactin regulation.",
      "id": "PETH-0558"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "GABA is the main inhibitory NT; benzodiazepines enhance GABA-A function but do not directly open chloride channels. Glutamate is the main excitatory NT; NMDA receptors are involved in learning and excitotoxicity.",
      "id": "PETH-0559"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Acetylcholine -- memory and attention; degeneration of cholinergic neurons causes Alzheimer's cognitive decline. Anticholinergic side effects are among the most tested pharmacology topics.",
      "id": "PETH-0560"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "The four dopamine pathways explain both the therapeutic and adverse effects of antipsychotics. Know mesolimbic (positive symptoms), mesocortical (negative/cognitive symptoms), nigrostriatal (EPS), and tuberoinfundibular (hyperprolactinemia).",
      "id": "PETH-0561"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "The FDA black box warning on all antidepressants warns of increased suicidality risk in patients under age 25. Fluoxetine is one of the few SSRIs with FDA approval for pediatric depression.",
      "id": "PETH-0562"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Geriatric pharmacology: \"Start low, go slow.\" Elderly patients have decreased hepatic/renal clearance, increased anticholinergic sensitivity, and polypharmacy risks. The Beers Criteria lists medications inappropriate for older adults.",
      "id": "PETH-0563"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Valproate (category X) is the most teratogenic mood stabilizer (neural tube defects); lithium is associated with Ebstein's anomaly (cardiac); carbamazepine also causes neural tube defects. The old A-X pregnancy categories have been replaced by narrative labeling (PLLR).",
      "id": "PETH-0564"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Renal impairment is most critical for lithium (entirely renally excreted); hepatic impairment affects most other psychotropics. Dose adjustments and closer monitoring are required for both.",
      "id": "PETH-0565"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Paroxetine is category D among SSRIs (cardiac teratogenicity risk); sertraline is generally preferred during breastfeeding due to low transfer into breast milk.",
      "id": "PETH-0566"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Excretion (Elimination)",
      "passage_type": "paragraph",
      "passage": "Excretion is the removal of drugs and their metabolites from the body. The two primary routes are:",
      "id": "PETH-0567"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Wide Therapeutic Index Drugs",
      "passage_type": "paragraph",
      "passage": "Drugs with a wide TI have a large margin of safety. Routine blood level monitoring is generally not necessary.",
      "id": "PETH-0568"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Pharmacokinetic Interactions",
      "passage_type": "paragraph",
      "passage": "These interactions alter the ADME of one drug by another, changing the drug's plasma concentration:",
      "id": "PETH-0569"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "pharma-foundations.html",
      "chapter_title": "Pharmacological Foundations & Neurotransmitter Systems",
      "section": "Renal and Hepatic Impairment",
      "passage_type": "paragraph",
      "passage": "Dosing adjustments are required when patients have impaired organ function that affects drug metabolism or excretion:",
      "id": "PETH-0570"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Standard 4.02: Discussing the Limits of Confidentiality",
      "passage_type": "paragraph",
      "passage": "At the outset of the relationship (preferably during the informed consent process)",
      "id": "PETH-0571"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Common Limits of Confidentiality",
      "passage_type": "paragraph",
      "passage": "Danger to self -- When a client poses an imminent risk of suicide or serious self-harm",
      "id": "PETH-0572"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Common Limits of Confidentiality",
      "passage_type": "paragraph",
      "passage": "Danger to others -- When a client poses a credible threat of violence toward an identifiable third party (Tarasoff duty)",
      "id": "PETH-0573"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Common Limits of Confidentiality",
      "passage_type": "paragraph",
      "passage": "Child abuse or neglect -- All 50 states mandate reporting of suspected child abuse or neglect",
      "id": "PETH-0574"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Common Limits of Confidentiality",
      "passage_type": "paragraph",
      "passage": "Court orders -- A valid court order may require disclosure; a subpoena alone generally does not",
      "id": "PETH-0575"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Common Limits of Confidentiality",
      "passage_type": "paragraph",
      "passage": "Consultation -- Psychologists may disclose limited information for consultation purposes, typically without identifying the client",
      "id": "PETH-0576"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Psychotherapy Notes Under HIPAA",
      "passage_type": "paragraph",
      "passage": "Diagnosis, functional status, treatment plan, symptoms, prognosis, and progress to date",
      "id": "PETH-0577"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Confidentiality with Minors",
      "passage_type": "paragraph",
      "passage": "Parents generally have the right to access their minor child's treatment records.",
      "id": "PETH-0578"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Confidentiality with Minors",
      "passage_type": "paragraph",
      "passage": "However, many practitioners negotiate a limited confidentiality agreement at the outset, explaining to both parents and the minor what will and will not be shared.",
      "id": "PETH-0579"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Confidentiality with Minors",
      "passage_type": "paragraph",
      "passage": "The psychologist should inform the minor about the limits of confidentiality in age-appropriate language.",
      "id": "PETH-0580"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Confidentiality with Minors",
      "passage_type": "paragraph",
      "passage": "In many states, minors can consent to their own mental health treatment at age 12-16 (depending on the jurisdiction), which may alter confidentiality obligations.",
      "id": "PETH-0581"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Confidentiality with Minors",
      "passage_type": "paragraph",
      "passage": "Mandatory reporting obligations (e.g., child abuse) always override confidentiality agreements with minors.",
      "id": "PETH-0582"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Confidentiality in Group Therapy",
      "passage_type": "paragraph",
      "passage": "Inform members that the psychologist cannot guarantee that other group members will not disclose information",
      "id": "PETH-0583"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Mandated Reporting",
      "passage_type": "paragraph",
      "passage": "Reporting is based on reasonable suspicion, not certainty. Psychologists do not need to conduct an investigation before reporting.",
      "id": "PETH-0584"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Mandated Reporting",
      "passage_type": "paragraph",
      "passage": "Most states extend mandated reporting to elder abuse and abuse of dependent adults.",
      "id": "PETH-0585"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Mandated Reporting",
      "passage_type": "paragraph",
      "passage": "Failure to report when mandated can result in criminal penalties, civil liability, and ethics violations.",
      "id": "PETH-0586"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Mandated Reporting",
      "passage_type": "paragraph",
      "passage": "Good-faith reports are typically protected by immunity statutes that shield reporters from liability even if the report proves unfounded.",
      "id": "PETH-0587"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Privilege belongs to the client, not the therapist. Only the client (or their legal representative) can waive privilege.",
      "id": "PETH-0588"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "A subpoena alone does not compel disclosure; a court order does. When receiving a subpoena, consult an attorney and notify the client.",
      "id": "PETH-0589"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "The Tarasoff duty requires a special relationship, a credible serious threat, and an identifiable victim. The duty to protect can be fulfilled by means other than warning the victim.",
      "id": "PETH-0590"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Under HIPAA, psychotherapy notes (process notes kept separately) receive extra protection and generally require separate authorization for disclosure.",
      "id": "PETH-0591"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "With minors, parents generally have access to records, but practitioners should negotiate confidentiality limits at the outset.",
      "id": "PETH-0592"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "In group therapy, the psychologist cannot guarantee other members' confidentiality but must establish clear expectations.",
      "id": "PETH-0593"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Mandated reporting (child abuse, elder abuse) overrides confidentiality and privilege, and is based on reasonable suspicion, not certainty.",
      "id": "PETH-0594"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Common Limits of Confidentiality",
      "passage_type": "paragraph",
      "passage": "The following situations typically require or permit disclosure of otherwise confidential information:",
      "id": "PETH-0595"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "privacy-confidentiality.html",
      "chapter_title": "Privacy & Confidentiality (Std 4)",
      "section": "Mandated Reporting",
      "passage_type": "paragraph",
      "passage": "Psychologists are mandated reporters in all 50 states for suspected child abuse and neglect. Key points:",
      "id": "PETH-0596"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Legal and Ethical Responsibilities of Supervisors",
      "passage_type": "paragraph",
      "passage": "Vicarious liability (respondeat superior): Supervisors may be held legally responsible for the negligent acts of their supervisees. The supervisor has a duty to properly oversee the supervisee's work.",
      "id": "PETH-0597"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Legal and Ethical Responsibilities of Supervisors",
      "passage_type": "paragraph",
      "passage": "Direct liability: Supervisors can be held directly liable for their own negligent supervision (e.g., failing to review cases, providing inadequate guidance, failing to identify supervisee impairment).",
      "id": "PETH-0598"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Legal and Ethical Responsibilities of Supervisors",
      "passage_type": "paragraph",
      "passage": "Supervisors must establish clear expectations, provide regular feedback, document supervision sessions, and ensure supervisees practice within their competence.",
      "id": "PETH-0599"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Legal and Ethical Responsibilities of Supervisors",
      "passage_type": "paragraph",
      "passage": "Supervisors must not engage in sexual relationships with supervisees (Standard 7.07).",
      "id": "PETH-0600"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Legal and Ethical Responsibilities of Supervisors",
      "passage_type": "paragraph",
      "passage": "The informed consent process in therapy should include disclosure that the therapist is being supervised and the supervisor's name and role.",
      "id": "PETH-0601"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Typical Licensure Requirements",
      "passage_type": "paragraph",
      "passage": "Doctoral degree in psychology from an accredited program (APA or CPA accredited, or equivalent)",
      "id": "PETH-0602"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Typical Licensure Requirements",
      "passage_type": "paragraph",
      "passage": "Additional state-specific requirements (e.g., jurisprudence exam, oral examination, state-specific written exam)",
      "id": "PETH-0603"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Scope of Practice",
      "passage_type": "paragraph",
      "passage": "Scope varies significantly across states (e.g., some states permit psychologists to prescribe medications, most do not)",
      "id": "PETH-0604"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Scope of Practice",
      "passage_type": "paragraph",
      "passage": "Practice acts may define psychology broadly (e.g., \"the assessment and treatment of mental and emotional disorders\") or narrowly",
      "id": "PETH-0605"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Scope of Practice",
      "passage_type": "paragraph",
      "passage": "Practicing outside one's legally defined scope of practice can result in charges of practicing without a license",
      "id": "PETH-0606"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Scope of Practice",
      "passage_type": "paragraph",
      "passage": "Scope of practice laws serve a consumer protection function by ensuring only qualified individuals provide psychological services",
      "id": "PETH-0607"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Prescriptive Authority",
      "passage_type": "paragraph",
      "passage": "Currently, psychologists in a small number of jurisdictions have obtained prescriptive authority (e.g., New Mexico, Louisiana, Illinois, Iowa, Idaho, Colorado, and the U.S. military and Indian Health Service)",
      "id": "PETH-0608"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Prescriptive Authority",
      "passage_type": "paragraph",
      "passage": "Prescriptive authority typically requires additional postdoctoral training in psychopharmacology (a master's-level program in clinical psychopharmacology)",
      "id": "PETH-0609"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Prescriptive Authority",
      "passage_type": "paragraph",
      "passage": "The APA has adopted a policy supporting the pursuit of prescriptive authority for appropriately trained psychologists",
      "id": "PETH-0610"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Prescriptive Authority",
      "passage_type": "paragraph",
      "passage": "Opposition comes primarily from organized medicine (AMA) and some within psychology who argue it changes the profession's identity",
      "id": "PETH-0611"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Prescriptive Authority",
      "passage_type": "paragraph",
      "passage": "The Department of Defense's Psychopharmacology Demonstration Project (PDP) demonstrated that appropriately trained psychologists could safely and effectively prescribe medications",
      "id": "PETH-0612"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Telepsychology",
      "passage_type": "paragraph",
      "passage": "Competence: Psychologists must be competent in the use of the technology and understand its limitations",
      "id": "PETH-0613"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Telepsychology",
      "passage_type": "paragraph",
      "passage": "Informed consent: Must address the unique risks of telehealth (privacy, technology failures, emergency protocols)",
      "id": "PETH-0614"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Telepsychology",
      "passage_type": "paragraph",
      "passage": "Confidentiality: Use of encrypted, HIPAA-compliant platforms; awareness of risks to privacy in the client's environment",
      "id": "PETH-0615"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Telepsychology",
      "passage_type": "paragraph",
      "passage": "Interjurisdictional practice: Psychologists must be licensed in the state where the client is located (this is the most common regulatory challenge); PSYPACT (Psychology Interjurisdictional Compact) allows telepsychology across participating states",
      "id": "PETH-0616"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Telepsychology",
      "passage_type": "paragraph",
      "passage": "Emergency management: Providers must have a plan for managing crises when the client is at a remote location (e.g., knowing local emergency resources)",
      "id": "PETH-0617"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Telepsychology",
      "passage_type": "paragraph",
      "passage": "APA Guidelines: The APA published Guidelines for the Practice of Telepsychology (2013) addressing these issues",
      "id": "PETH-0618"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Forensic Concepts",
      "passage_type": "paragraph",
      "passage": "Dual-role conflicts: Psychologists should generally avoid serving as both therapist and forensic evaluator for the same client (different obligations, potential for conflicting interests)",
      "id": "PETH-0619"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Forensic Concepts",
      "passage_type": "paragraph",
      "passage": "Competence to stand trial: The legal standard (from Dusky v. United States, 1960) requires that the defendant has a rational and factual understanding of the proceedings and can consult with their attorney",
      "id": "PETH-0620"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Forensic Concepts",
      "passage_type": "paragraph",
      "passage": "Insanity defense: Various legal standards exist (M'Naghten, ALI/Model Penal Code, irresistible impulse); most require showing the defendant did not know the nature/quality of the act or that it was wrong",
      "id": "PETH-0621"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Forensic Concepts",
      "passage_type": "paragraph",
      "passage": "Custody evaluations: The standard is the \"best interests of the child\"; evaluators must be impartial and evaluate all parties involved",
      "id": "PETH-0622"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Forensic Concepts",
      "passage_type": "paragraph",
      "passage": "Risk assessment: Predicting future violence (actuarial tools vs. clinical judgment vs. structured professional judgment)",
      "id": "PETH-0623"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Specialty Guidelines for Forensic Psychology",
      "passage_type": "paragraph",
      "passage": "Clarification of the psychologist's role (who is the client -- the retaining party, the examinee, or the court?)",
      "id": "PETH-0624"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Record Keeping and Retention",
      "passage_type": "paragraph",
      "passage": "APA guidelines recommend retaining records for a minimum of 7 years after the last date of service for adults, and 3 years after a minor reaches age of majority",
      "id": "PETH-0625"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Record Keeping and Retention",
      "passage_type": "paragraph",
      "passage": "Records must be maintained securely and disposed of in a manner that protects confidentiality (e.g., shredding, secure electronic deletion)",
      "id": "PETH-0626"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Record Keeping and Retention",
      "passage_type": "paragraph",
      "passage": "Psychologists should plan for record transfer in the event of incapacity, retirement, or death",
      "id": "PETH-0627"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Managed Care Issues",
      "passage_type": "paragraph",
      "passage": "Psychologists must balance the financial constraints of managed care with their ethical obligations to clients",
      "id": "PETH-0628"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Managed Care Issues",
      "passage_type": "paragraph",
      "passage": "If a managed care organization limits sessions, the psychologist must inform the client and advocate for continued treatment if clinically needed",
      "id": "PETH-0629"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Managed Care Issues",
      "passage_type": "paragraph",
      "passage": "Psychologists should not provide inaccurate diagnoses solely to obtain insurance reimbursement",
      "id": "PETH-0630"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "APA Telepsychology Guidelines (2013)",
      "passage_type": "paragraph",
      "passage": "Informed consent for telehealth: Psychologists must obtain informed consent that specifically addresses the unique risks of technology-mediated services, including potential breaches of confidentiality, technology failures, procedures for emergencies, and the limitations of the medium (e.g., inability to read nonverbal cues fully via telephone).",
      "id": "PETH-0631"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "APA Telepsychology Guidelines (2013)",
      "passage_type": "paragraph",
      "passage": "Competence in technology: Psychologists must ensure they are competent not only in the clinical services they provide but also in the technology used to deliver them. This includes understanding encryption, platform security, data storage, and how to troubleshoot common technical issues.",
      "id": "PETH-0632"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "APA Telepsychology Guidelines (2013)",
      "passage_type": "paragraph",
      "passage": "Confidentiality risks: Telehealth introduces risks that do not exist in traditional face-to-face practice -- data breaches, unsecured Wi-Fi networks, screen visibility in the client's environment, and the possibility that others may overhear or observe sessions on the client's end.",
      "id": "PETH-0633"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "APA Telepsychology Guidelines (2013)",
      "passage_type": "paragraph",
      "passage": "Interjurisdictional practice: Psychologists must be aware of and comply with laws governing the practice of psychology in the jurisdiction where the client is located, not just where the psychologist is located.",
      "id": "PETH-0634"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Social Media Boundary Issues",
      "passage_type": "paragraph",
      "passage": "Googling clients: Searching for client information online without their knowledge or consent raises ethical concerns regarding privacy and the therapeutic relationship. Some argue it can compromise clinical objectivity by introducing extraclinical information. The APA has not issued a blanket prohibition, but psychologists should carefully consider whether the information is clinically necessary, document the rationale, and consider discussing the search with the client.",
      "id": "PETH-0635"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Social Media Boundary Issues",
      "passage_type": "paragraph",
      "passage": "Accepting friend/follow requests: Psychologists should generally not accept friend or follow requests from current clients on personal social media accounts, as this constitutes a boundary crossing (or boundary violation) that compromises professional objectivity and confidentiality. Even acknowledging a therapeutic relationship online could breach confidentiality.",
      "id": "PETH-0636"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Social Media Boundary Issues",
      "passage_type": "paragraph",
      "passage": "Social media discovery: Clients may search for information about their psychologist online. Psychologists should proactively manage their digital footprint and consider discussing social media boundaries during the informed consent process.",
      "id": "PETH-0637"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Social Media Boundary Issues",
      "passage_type": "paragraph",
      "passage": "Testimonials and endorsements: The APA Ethics Code (Standard 5.05) prohibits psychologists from soliciting testimonials from current clients or others who, because of their circumstances, are vulnerable to undue influence. Online reviews and social media endorsements present modern challenges to this standard.",
      "id": "PETH-0638"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Email and Text Communication with Clients",
      "passage_type": "paragraph",
      "passage": "Email and text messages sent between psychologists and clients become part of the clinical record and are potentially discoverable in legal proceedings.",
      "id": "PETH-0639"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Email and Text Communication with Clients",
      "passage_type": "paragraph",
      "passage": "Standard email and SMS are not encrypted and do not meet HIPAA security requirements. Psychologists should use encrypted email platforms or secure patient portals when communicating clinical information electronically.",
      "id": "PETH-0640"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Email and Text Communication with Clients",
      "passage_type": "paragraph",
      "passage": "Informed consent should specify the acceptable methods and scope of electronic communication (e.g., email for scheduling only, not clinical content).",
      "id": "PETH-0641"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Email and Text Communication with Clients",
      "passage_type": "paragraph",
      "passage": "Response time expectations should be established clearly -- clients should be informed that email and text are not appropriate for emergencies.",
      "id": "PETH-0642"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Online Therapy Platforms and HIPAA Compliance",
      "passage_type": "paragraph",
      "passage": "All platforms used for telehealth must be HIPAA-compliant, meaning they employ end-to-end encryption, have signed Business Associate Agreements (BAAs) with the provider, and maintain appropriate data storage and access controls.",
      "id": "PETH-0643"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Online Therapy Platforms and HIPAA Compliance",
      "passage_type": "paragraph",
      "passage": "Consumer-grade platforms (e.g., standard Zoom, FaceTime, Skype) were temporarily permitted during the COVID-19 public health emergency, but standard practice requires HIPAA-compliant platforms.",
      "id": "PETH-0644"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Online Therapy Platforms and HIPAA Compliance",
      "passage_type": "paragraph",
      "passage": "Psychologists are responsible for verifying platform compliance regardless of what the platform company claims.",
      "id": "PETH-0645"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Digital Native vs. Digital Immigrant Considerations",
      "passage_type": "paragraph",
      "passage": "Younger clients may prefer text-based communication and may have different expectations about response times and platform accessibility.",
      "id": "PETH-0646"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Digital Native vs. Digital Immigrant Considerations",
      "passage_type": "paragraph",
      "passage": "Older clients may be less comfortable with technology and may require additional support in using telehealth platforms.",
      "id": "PETH-0647"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Digital Native vs. Digital Immigrant Considerations",
      "passage_type": "paragraph",
      "passage": "Psychologists must assess each client's technological competence and comfort level as part of the informed consent process for telepsychology.",
      "id": "PETH-0648"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Digital Native vs. Digital Immigrant Considerations",
      "passage_type": "paragraph",
      "passage": "Training programs are increasingly recognizing the need to prepare psychologists for technology-mediated practice, but a significant generational competence gap may exist among practitioners.",
      "id": "PETH-0649"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Social Media Posts by Psychologists",
      "passage_type": "paragraph",
      "passage": "Public posts expressing strong political, religious, or social opinions may affect the therapeutic relationship with clients who hold different views and may encounter those posts.",
      "id": "PETH-0650"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Social Media Posts by Psychologists",
      "passage_type": "paragraph",
      "passage": "Sharing clinical vignettes on social media -- even when de-identified -- risks breaching confidentiality if clients recognize themselves or if the details are insufficient to fully obscure identity.",
      "id": "PETH-0651"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Social Media Posts by Psychologists",
      "passage_type": "paragraph",
      "passage": "Psychologists should consider maintaining separate personal and professional social media accounts.",
      "id": "PETH-0652"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Social Media Posts by Psychologists",
      "passage_type": "paragraph",
      "passage": "Self-disclosure through social media is involuntary and ongoing, unlike controlled self-disclosure in therapy, and its effects on the therapeutic relationship may be unpredictable.",
      "id": "PETH-0653"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Electroconvulsive Therapy (ECT)",
      "passage_type": "paragraph",
      "passage": "Mechanism: The exact mechanism is unknown, but theories include enhanced GABAergic transmission, serotonin sensitization, increased BDNF (brain-derived neurotrophic factor), normalization of HPA axis function, and anticonvulsant effects from repeated seizure induction.",
      "id": "PETH-0654"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Electroconvulsive Therapy (ECT)",
      "passage_type": "paragraph",
      "passage": "Indications: Severe treatment-resistant depression, depression with psychotic features, acute suicidality (ECT has the fastest onset of antidepressant effect of any treatment), catatonia, severe mania unresponsive to medications, and (rarely) treatment-resistant schizophrenia.",
      "id": "PETH-0655"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Electroconvulsive Therapy (ECT)",
      "passage_type": "paragraph",
      "passage": "Electrode placement: Bilateral (bitemporal) placement is generally more effective but associated with greater cognitive side effects. Right unilateral (non-dominant hemisphere) placement produces fewer cognitive side effects while maintaining efficacy when administered at adequate stimulus intensity (typically 6x seizure threshold).",
      "id": "PETH-0656"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Electroconvulsive Therapy (ECT)",
      "passage_type": "paragraph",
      "passage": "Side effects: The primary cognitive side effect is retrograde amnesia (loss of memories formed before treatment), which is usually temporary but can be persistent for events close in time to the treatment. Anterograde amnesia (difficulty forming new memories) also occurs acutely but typically resolves within weeks. Headache and muscle soreness are common transient effects.",
      "id": "PETH-0657"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Electroconvulsive Therapy (ECT)",
      "passage_type": "paragraph",
      "passage": "Course: A typical acute course involves 6-12 sessions (usually 3 per week), with noticeable improvement often occurring after 2-4 treatments. Maintenance ECT (weekly to monthly sessions) may be used to prevent relapse.",
      "id": "PETH-0658"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Transcranial Magnetic Stimulation (TMS)",
      "passage_type": "paragraph",
      "passage": "Mechanism: A magnetic coil placed against the scalp generates rapidly alternating magnetic fields that induce electrical currents in underlying cortical tissue. Repetitive TMS (rTMS) -- the form used therapeutically -- applies repeated pulses to produce lasting changes in neural excitability.",
      "id": "PETH-0659"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Transcranial Magnetic Stimulation (TMS)",
      "passage_type": "paragraph",
      "passage": "FDA-cleared indications: Treatment-resistant major depressive disorder (MDD) -- the primary indication -- and obsessive-compulsive disorder (OCD). The FDA clearance for depression targets the left dorsolateral prefrontal cortex (DLPFC), an area associated with reduced activity in depression.",
      "id": "PETH-0660"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Transcranial Magnetic Stimulation (TMS)",
      "passage_type": "paragraph",
      "passage": "High-frequency vs. low-frequency: High-frequency stimulation (e.g., 10 Hz) of the left DLPFC is excitatory and is the standard depression protocol. Low-frequency stimulation (e.g., 1 Hz) is inhibitory and may be used on the right DLPFC or for other applications.",
      "id": "PETH-0661"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Transcranial Magnetic Stimulation (TMS)",
      "passage_type": "paragraph",
      "passage": "Advantages over ECT: No anesthesia required, no seizure induced, no cognitive side effects (no memory impairment), outpatient procedure, can drive immediately after treatment.",
      "id": "PETH-0662"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Transcranial Magnetic Stimulation (TMS)",
      "passage_type": "paragraph",
      "passage": "Limitations: Generally less effective than ECT for severe treatment-resistant depression; requires daily sessions over 4-6 weeks (typical course: 20-30 sessions); rare risk of seizure (~0.1%).",
      "id": "PETH-0663"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Ketamine and Esketamine",
      "passage_type": "paragraph",
      "passage": "Mechanism: Ketamine is an NMDA receptor antagonist that triggers downstream effects including increased AMPA receptor signaling, enhanced BDNF release, and rapid synaptogenesis (formation of new synaptic connections). This represents a fundamentally different mechanism than traditional monoamine-based antidepressants.",
      "id": "PETH-0664"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Ketamine and Esketamine",
      "passage_type": "paragraph",
      "passage": "Onset of action: Antidepressant effects can occur within hours of a single infusion (compared to 4-8 weeks for SSRIs), making ketamine a potentially life-saving option for acutely suicidal patients.",
      "id": "PETH-0665"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Ketamine and Esketamine",
      "passage_type": "paragraph",
      "passage": "Administration: IV ketamine is administered off-label in clinical settings (infusion clinics). Esketamine (Spravato) nasal spray is FDA-approved and must be administered in a certified healthcare setting under direct observation due to dissociative effects and abuse potential (REMS program).",
      "id": "PETH-0666"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Ketamine and Esketamine",
      "passage_type": "paragraph",
      "passage": "Side effects: Dissociative symptoms (feeling detached from reality), dizziness, nausea, increased blood pressure, sedation. Effects are typically transient (resolving within 2 hours).",
      "id": "PETH-0667"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Ketamine and Esketamine",
      "passage_type": "paragraph",
      "passage": "Abuse potential: Ketamine is a Schedule III controlled substance with known abuse and dependence potential. This is a significant concern for long-term use and requires careful patient selection and monitoring.",
      "id": "PETH-0668"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Psychedelic-Assisted Therapy",
      "passage_type": "paragraph",
      "passage": "Psilocybin for depression: Psilocybin (the active compound in \"magic mushrooms\") has received FDA breakthrough therapy designation for treatment-resistant depression and major depressive disorder. It acts primarily as a 5-HT2A receptor agonist, producing profound alterations in consciousness that, when combined with psychological support, may lead to lasting improvements in mood and outlook.",
      "id": "PETH-0669"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Psychedelic-Assisted Therapy",
      "passage_type": "paragraph",
      "passage": "MDMA for PTSD: MDMA (3,4-methylenedioxymethamphetamine) has been studied in Phase 3 clinical trials for PTSD. MDMA-assisted therapy involves administering MDMA in conjunction with psychotherapy sessions; the MDMA is hypothesized to reduce fear responses and enhance therapeutic alliance, facilitating trauma processing. MDMA increases release of serotonin, dopamine, norepinephrine, and oxytocin.",
      "id": "PETH-0670"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Psychedelic-Assisted Therapy",
      "passage_type": "paragraph",
      "passage": "Therapeutic model: Unlike traditional pharmacotherapy (daily medication), psychedelic-assisted therapy typically involves only 1-3 dosing sessions, each accompanied by extensive preparatory and integration psychotherapy sessions. The psychotherapy component is considered integral to the treatment, not incidental.",
      "id": "PETH-0671"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Psychedelic-Assisted Therapy",
      "passage_type": "paragraph",
      "passage": "Regulatory status: As of the mid-2020s, these substances remain Schedule I controlled substances for general use. Clinical use requires specific regulatory authorization (FDA-approved clinical trials, or state-level exemptions where available).",
      "id": "PETH-0672"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Malpractice requires proving all Four D's: Duty, Dereliction, Damage, and Direct causation.",
      "id": "PETH-0673"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Sexual misconduct is the most common basis for ethics complaints against psychologists.",
      "id": "PETH-0674"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Supervisors are liable for supervisees' acts (vicarious liability) and for their own negligent supervision (direct liability).",
      "id": "PETH-0675"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Licensure is mandatory and state-regulated; certification (e.g., ABPP) is voluntary and indicates specialty competence.",
      "id": "PETH-0676"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Practicing outside the legal scope of practice constitutes practicing without a license.",
      "id": "PETH-0677"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Prescriptive authority for psychologists exists in a limited number of states and requires additional postdoctoral training.",
      "id": "PETH-0678"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "In telepsychology, psychologists must be licensed where the client is located; PSYPACT facilitates interstate practice.",
      "id": "PETH-0679"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Forensic psychologists should avoid dual-role conflicts (therapist and forensic evaluator for the same person).",
      "id": "PETH-0680"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Competency to stand trial (Dusky standard) requires rational/factual understanding of proceedings and ability to consult with counsel.",
      "id": "PETH-0681"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "APA recommends retaining adult records for 7 years after last service; for minors, 3 years after reaching majority.",
      "id": "PETH-0682"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Telepsychology informed consent must address technology-specific risks (data breaches, emergency protocols, platform security) beyond standard informed consent elements.",
      "id": "PETH-0683"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Psychologists should generally not accept social media friend/follow requests from current clients -- this constitutes a boundary crossing that compromises confidentiality and professional objectivity.",
      "id": "PETH-0684"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Email and text communications with clients become part of the clinical record and must use encrypted, HIPAA-compliant channels for clinical content.",
      "id": "PETH-0685"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "ECT is the fastest-acting treatment for severe depression and acute suicidality; retrograde amnesia is its primary cognitive side effect; right unilateral placement produces fewer cognitive effects than bilateral.",
      "id": "PETH-0686"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "TMS (repetitive TMS targeting the left DLPFC) is FDA-cleared for treatment-resistant MDD and OCD; it is non-invasive, requires no anesthesia, and causes no cognitive side effects.",
      "id": "PETH-0687"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Ketamine/esketamine are NMDA antagonists producing rapid antidepressant effects (within hours); esketamine (Spravato) nasal spray is FDA-approved for treatment-resistant depression but carries abuse potential and dissociative side effects.",
      "id": "PETH-0688"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Psilocybin (5-HT2A agonist) has FDA breakthrough therapy designation for depression; MDMA-assisted therapy has been studied in Phase 3 trials for PTSD.",
      "id": "PETH-0689"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "The Four D's of Malpractice",
      "passage_type": "paragraph",
      "passage": "To prevail in a malpractice lawsuit, the plaintiff must prove all four elements (the \"Four D's\"):",
      "id": "PETH-0690"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "The Four D's of Malpractice",
      "passage_type": "paragraph",
      "passage": "All four elements must be established. If any one is missing, the malpractice claim fails.",
      "id": "PETH-0691"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Specialty Guidelines for Forensic Psychology",
      "passage_type": "paragraph",
      "passage": "The APA published the Specialty Guidelines for Forensic Psychology (2013), which address:",
      "id": "PETH-0692"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "professional-issues.html",
      "chapter_title": "Professional Practice Issues",
      "section": "Social Media Posts by Psychologists",
      "passage_type": "paragraph",
      "passage": "Psychologists who maintain a social media presence must be mindful of maintaining professional boundaries publicly:",
      "id": "PETH-0693"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "6.02: Maintenance, Dissemination, and Disposal of Records",
      "passage_type": "paragraph",
      "passage": "Planning in advance to facilitate the appropriate transfer and protection of records in the event of withdrawal from practice, incapacity, or death",
      "id": "PETH-0694"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Records needed for emergency treatment may not be withheld for nonpayment (Standard 6.03).",
      "id": "PETH-0695"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Bartering is permissible when it is not clinically contraindicated and not exploitative.",
      "id": "PETH-0696"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Fee arrangements should be established as early as feasible in the professional relationship.",
      "id": "PETH-0697"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Referral fees (paying or receiving fees solely for the referral) are prohibited; fees must be based on services actually provided.",
      "id": "PETH-0698"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Fraudulent billing practices (upcoding, billing for services not rendered, inaccurate diagnoses for reimbursement) are serious ethical violations.",
      "id": "PETH-0699"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "record-keeping-fees.html",
      "chapter_title": "Record Keeping & Fees (Std 6)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Psychologists must plan in advance for the transfer and protection of records in the event of withdrawal from practice, incapacity, or death.",
      "id": "PETH-0700"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.02: Informed Consent to Research",
      "passage_type": "paragraph",
      "passage": "Reasonably foreseeable factors that may influence willingness to participate (e.g., potential risks, discomfort, adverse effects)",
      "id": "PETH-0701"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.05: Dispensing with Informed Consent for Research",
      "passage_type": "paragraph",
      "passage": "The research would not reasonably be assumed to create distress or harm, AND involves (a) the study of normal educational practices in educational settings, (b) anonymous questionnaires or naturalistic observation where disclosure would not place participants at risk, or (c) the study of factors related to job effectiveness conducted in organizational settings with no effect on employment",
      "id": "PETH-0702"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.07: Deception in Research",
      "passage_type": "paragraph",
      "passage": "The use of deception is justified by the study's significant prospective scientific, educational, or applied value",
      "id": "PETH-0703"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.07: Deception in Research",
      "passage_type": "paragraph",
      "passage": "Participants are not deceived about significant aspects that would affect their willingness to participate (such as physical risks, discomfort, or unpleasant emotional experiences)",
      "id": "PETH-0704"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.09: Humane Care and Use of Animals in Research",
      "passage_type": "paragraph",
      "passage": "Acquire, care for, use, and dispose of animals in compliance with federal, state, and local laws and regulations, and with professional standards",
      "id": "PETH-0705"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.09: Humane Care and Use of Animals in Research",
      "passage_type": "paragraph",
      "passage": "Ensure that individuals under their supervision who use animals have been instructed in research methods and in the care, maintenance, and handling of the species being used",
      "id": "PETH-0706"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.09: Humane Care and Use of Animals in Research",
      "passage_type": "paragraph",
      "passage": "Make reasonable efforts to minimize the discomfort, infection, illness, and pain of animals",
      "id": "PETH-0707"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.09: Humane Care and Use of Animals in Research",
      "passage_type": "paragraph",
      "passage": "Use procedures subjecting animals to pain, stress, or privation only when an alternative procedure is unavailable and the goal is justified by its prospective scientific, educational, or applied value",
      "id": "PETH-0708"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.09: Humane Care and Use of Animals in Research",
      "passage_type": "paragraph",
      "passage": "Perform surgical procedures under appropriate anesthesia and use techniques to avoid infection and minimize pain",
      "id": "PETH-0709"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.09: Humane Care and Use of Animals in Research",
      "passage_type": "paragraph",
      "passage": "When it is appropriate that an animal's life be terminated, proceed rapidly and painlessly",
      "id": "PETH-0710"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "The Belmont Report established three principles: respect for persons, beneficence, and justice.",
      "id": "PETH-0711"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Deception is permissible only when justified by significant value, non-deceptive alternatives are not feasible, and participants are not deceived about significant risks.",
      "id": "PETH-0712"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Debriefing must occur as soon as possible after participation and must explain any deception used.",
      "id": "PETH-0713"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Students should be listed as principal author on publications substantially based on their doctoral dissertation.",
      "id": "PETH-0714"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Institutional position alone does not justify authorship credit; credit must reflect actual contribution.",
      "id": "PETH-0715"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Research data must be shared for verification after publication, with appropriate confidentiality protections.",
      "id": "PETH-0716"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "When research participation is required for a course, equitable alternatives must be offered to students who decline.",
      "id": "PETH-0717"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "The Belmont Report (1979)",
      "passage_type": "paragraph",
      "passage": "The Belmont Report established the three foundational ethical principles for research involving human subjects:",
      "id": "PETH-0718"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.02: Informed Consent to Research",
      "passage_type": "paragraph",
      "passage": "When obtaining informed consent for research, psychologists inform participants about:",
      "id": "PETH-0719"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.05: Dispensing with Informed Consent for Research",
      "passage_type": "paragraph",
      "passage": "Psychologists may dispense with informed consent only when:",
      "id": "PETH-0720"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.07: Deception in Research",
      "passage_type": "paragraph",
      "passage": "Deception in research is permissible only when:",
      "id": "PETH-0721"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "research-publication.html",
      "chapter_title": "Research & Publication (Std 8)",
      "section": "8.09: Humane Care and Use of Animals in Research",
      "passage_type": "paragraph",
      "passage": "Psychologists who use animals in research must:",
      "id": "PETH-0722"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "When ethics conflict with law, psychologists must clarify the conflict, make known their commitment to the Ethics Code, and take reasonable steps to resolve it (Standard 1.02). This never permits violating human rights.",
      "id": "PETH-0723"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "The first response to learning of a colleague's ethical violation is usually informal resolution (Standard 1.04) -- bringing it to the colleague's attention -- UNLESS doing so would violate confidentiality or the violation is too serious for informal resolution.",
      "id": "PETH-0724"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "When informal resolution is not appropriate, the psychologist should take further action such as referral to an ethics committee or licensing board (Standard 1.05).",
      "id": "PETH-0725"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Cooperating with ethics investigations is mandatory; failure to cooperate is itself an ethics violation (Standard 1.06).",
      "id": "PETH-0726"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Filing an ethics complaint with reckless disregard for the facts is prohibited (Standard 1.07).",
      "id": "PETH-0727"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Psychologists may not retaliate against those who file ethics complaints (Standard 1.08).",
      "id": "PETH-0728"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "resolving-ethical-issues.html",
      "chapter_title": "Resolving Ethical Issues (Std 1)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "If a psychologist's work is being misused or misrepresented, they must take reasonable steps to correct or minimize the misuse (Standard 1.01).",
      "id": "PETH-0729"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "stimulants-adhd.html",
      "chapter_title": "Stimulants & ADHD Meds",
      "section": "Side Effects of Stimulants",
      "passage_type": "paragraph",
      "passage": "Growth suppression in children (controversial; may slow growth velocity but generally does not affect final adult height)",
      "id": "PETH-0730"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "stimulants-adhd.html",
      "chapter_title": "Stimulants & ADHD Meds",
      "section": "Atomoxetine (Strattera)",
      "passage_type": "paragraph",
      "passage": "Advantages: Not a controlled substance; no abuse potential; useful for patients with comorbid substance use disorders or anxiety; continuous 24-hour coverage",
      "id": "PETH-0731"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "stimulants-adhd.html",
      "chapter_title": "Stimulants & ADHD Meds",
      "section": "Atomoxetine (Strattera)",
      "passage_type": "paragraph",
      "passage": "Disadvantages: Takes 4-6 weeks for full effect; less effective than stimulants for many patients; FDA black box warning for suicidal ideation in children and adolescents",
      "id": "PETH-0732"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "stimulants-adhd.html",
      "chapter_title": "Stimulants & ADHD Meds",
      "section": "Atomoxetine (Strattera)",
      "passage_type": "paragraph",
      "passage": "Side effects: GI upset, decreased appetite, dizziness, mood changes, potential hepatotoxicity (rare)",
      "id": "PETH-0733"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "stimulants-adhd.html",
      "chapter_title": "Stimulants & ADHD Meds",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Stimulants (methylphenidate, amphetamines) are the first-line pharmacological treatment for ADHD and increase dopamine and norepinephrine activity.",
      "id": "PETH-0734"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "stimulants-adhd.html",
      "chapter_title": "Stimulants & ADHD Meds",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Atomoxetine is a non-stimulant alternative (selective NRI) with no abuse potential; takes 4-6 weeks for full effect.",
      "id": "PETH-0735"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "stimulants-adhd.html",
      "chapter_title": "Stimulants & ADHD Meds",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Stimulants are Schedule II controlled substances with potential for abuse and dependence.",
      "id": "PETH-0736"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "stimulants-adhd.html",
      "chapter_title": "Stimulants & ADHD Meds",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Common side effects include decreased appetite, insomnia, and increased heart rate/blood pressure.",
      "id": "PETH-0737"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "stimulants-adhd.html",
      "chapter_title": "Stimulants & ADHD Meds",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Lisdexamfetamine (Vyvanse) is a prodrug formulation that reduces abuse potential.",
      "id": "PETH-0738"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "stimulants-adhd.html",
      "chapter_title": "Stimulants & ADHD Meds",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Growth suppression in children is possible but generally does not affect final adult height.",
      "id": "PETH-0739"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "stimulants-adhd.html",
      "chapter_title": "Stimulants & ADHD Meds",
      "section": "Atomoxetine (Strattera)",
      "passage_type": "paragraph",
      "passage": "Atomoxetine is a non-stimulant medication for ADHD:",
      "id": "PETH-0740"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Standard 10.08: Sexual Intimacies with Former Therapy Clients",
      "passage_type": "paragraph",
      "passage": "Any statements or actions made by the therapist during therapy suggesting or inviting a posttermination sexual or romantic relationship",
      "id": "PETH-0741"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Informed consent to therapy must include information about the nature and course of therapy, fees, confidentiality limits, risks and benefits, alternatives, and the right to withdraw (10.01).",
      "id": "PETH-0742"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "In couples/family therapy, the psychologist must clarify roles, identify who the client(s) are, and address potential conflicts at the outset (10.02).",
      "id": "PETH-0743"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "In group therapy, the psychologist cannot guarantee other members' confidentiality and must disclose this limitation (10.03).",
      "id": "PETH-0744"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Providing therapy to someone already seen by another provider requires careful consideration and consultation -- it is not prohibited but must be handled thoughtfully (10.04).",
      "id": "PETH-0745"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Sexual intimacies with current clients and their relatives/significant others are always prohibited (10.05, 10.06).",
      "id": "PETH-0746"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Psychologists may never accept former sexual partners as therapy clients (10.07).",
      "id": "PETH-0747"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Sexual intimacies with former clients are prohibited for at least two years after termination, and even then only in the most unusual circumstances (10.08).",
      "id": "PETH-0748"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Termination should occur when the client has met goals, is not benefiting, or is being harmed (10.10). Pretermination counseling and referrals should be provided.",
      "id": "PETH-0749"
    },
    {
      "domain_code": "PETH",
      "domain_name": "Psychopharmacology & Ethics",
      "chapter_file": "therapy-ethics.html",
      "chapter_title": "Therapy (Std 10)",
      "section": "Key Takeaways for the EPPP",
      "passage_type": "clinical_note",
      "passage": "Abandonment -- abruptly ending treatment without notice or referral -- is always an ethical violation.",
      "id": "PETH-0750"
    }
  ]
}